{"status": "ok", "message-type": "work-list", "message-version": "1.0.0", "message": {"facets": {}, "total-results": 125771, "items": [{"indexed": {"date-parts": [[2019, 12, 2]], "date-time": "2019-12-02T20:16:25Z", "timestamp": 1575317785527}, "reference-count": 10, "publisher": "Wiley", "issue": "1", "license": [{"URL": "http://doi.wiley.com/10.1002/tdm_license_1.1", "start": {"date-parts": [[2015, 9, 1]], "date-time": "2015-09-01T00:00:00Z", "timestamp": 1441065600000}, "delay-in-days": 2434, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2009, 1]]}, "DOI": "10.1111/j.1365-2141.2008.07424.x", "type": "journal-article", "created": {"date-parts": [[2008, 11, 3]], "date-time": "2008-11-03T05:44:48Z", "timestamp": 1225691088000}, "page": "138-140", "source": "Crossref", "is-referenced-by-count": 22, "title": ["MicroRNA-155 expression and outcome in diffuse large B-cell lymphoma"], "prefix": "10.1111", "volume": "144", "author": [{"given": "Inkyung", "family": "Jung", "sequence": "first", "affiliation": []}, {"given": "Ricardo C. T.", "family": "Aguiar", "sequence": "additional", "affiliation": []}], "member": "311", "reference": [{"key": "10.1111/j.1365-2141.2008.07424.x-BIB1", "doi-asserted-by": "crossref", "first-page": "7024", "DOI": "10.1073/pnas.0602266103", "article-title": "Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in E(mu)-miR155 transgenic mice", "volume": "103", "author": "Costinean", "year": "2006", "journal-title": "Proceedings of the National Academy of Sciences of the United States of America"}, {"key": "10.1111/j.1365-2141.2008.07424.x-BIB2", "doi-asserted-by": "crossref", "first-page": "596", "DOI": "10.1016/j.immuni.2008.04.012", "article-title": "Along came a spider: AID escapes a microRNA web", "volume": "28", "author": "Desiderio", "year": "2008", "journal-title": "Immunity"}, {"key": "10.1111/j.1365-2141.2008.07424.x-BIB3", "doi-asserted-by": "crossref", "first-page": "1096", "DOI": "10.1038/nature05992", "article-title": "A viral microRNA functions as an orthologue of cellular miR-155", "volume": "450", "author": "Gottwein", "year": "2007", "journal-title": "Nature"}, {"key": "10.1111/j.1365-2141.2008.07424.x-BIB4", "doi-asserted-by": "crossref", "first-page": "3318", "DOI": "10.1182/blood-2004-04-1558", "article-title": "Expression of the AID protein in normal and neoplastic B cells", "volume": "104", "author": "Pasqualucci", "year": "2004", "journal-title": "Blood"}, {"key": "10.1111/j.1365-2141.2008.07424.x-BIB5", "doi-asserted-by": "crossref", "first-page": "108", "DOI": "10.1038/ng.2007.35", "article-title": "AID is required for germinal center-derived lymphomagenesis", "volume": "40", "author": "Pasqualucci", "year": "2008", "journal-title": "Nature Genetics"}, {"key": "10.1111/j.1365-2141.2008.07424.x-BIB6", "doi-asserted-by": "crossref", "first-page": "8", "DOI": "10.1016/j.cancergencyto.2007.10.008", "article-title": "Coordinated expression of microRNA-155 and predicted target genes in diffuse large B-cell lymphoma", "volume": "181", "author": "Rai", "year": "2008", "journal-title": "Cancer Genetics and Cytogenetics"}, {"key": "10.1111/j.1365-2141.2008.07424.x-BIB7", "doi-asserted-by": "crossref", "first-page": "732", "DOI": "10.1111/j.1365-2141.2008.07237.x", "article-title": "MicroRNA signatures characterize diffuse large B-cell lymphomas and follicular lymphomas", "volume": "142", "author": "Roehle", "year": "2008", "journal-title": "British Journal of Haematology"}, {"key": "10.1111/j.1365-2141.2008.07424.x-BIB8", "doi-asserted-by": "crossref", "first-page": "1770", "DOI": "10.1182/blood-2005-02-0542", "article-title": "Comparison of genome profiles for identification of distinct subgroups of diffuse large B-cell lymphoma", "volume": "106", "author": "Tagawa", "year": "2005", "journal-title": "Blood"}, {"key": "10.1111/j.1365-2141.2008.07424.x-BIB9", "doi-asserted-by": "crossref", "first-page": "189", "DOI": "10.1016/j.ccr.2006.01.025", "article-title": "Unique microRNA molecular profiles in lung cancer diagnosis and prognosis", "volume": "9", "author": "Yanaihara", "year": "2006", "journal-title": "Cancer Cell"}, {"key": "10.1111/j.1365-2141.2008.07424.x-BIB10", "doi-asserted-by": "crossref", "first-page": "2654", "DOI": "10.1074/jbc.M708218200", "article-title": "B-cell receptor activation induces BIC/miR-155 expression through a conserved AP-1 element", "volume": "283", "author": "Yin", "year": "2008", "journal-title": "Journal of Biological Chemistry"}], "container-title": ["British Journal of Haematology"], "language": "en", "link": [{"URL": "https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1365-2141.2008.07424.x", "content-type": "unspecified", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 2, 15]], "date-time": "2019-02-15T07:57:23Z", "timestamp": 1550217443000}, "score": 49.91092, "issued": {"date-parts": [[2009, 1]]}, "references-count": 10, "journal-issue": {"published-print": {"date-parts": [[2009, 1]]}, "issue": "1"}, "URL": "http://dx.doi.org/10.1111/j.1365-2141.2008.07424.x", "relation": {"cites": []}, "ISSN": ["0007-1048", "1365-2141"], "issn-type": [{"value": "0007-1048", "type": "print"}, {"value": "1365-2141", "type": "electronic"}], "subject": ["Hematology"]}, {"indexed": {"date-parts": [[2019, 12, 2]], "date-time": "2019-12-02T16:59:40Z", "timestamp": 1575305980749}, "reference-count": 50, "publisher": "Elsevier BV", "issue": "3", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2001, 12, 1]], "date-time": "2001-12-01T00:00:00Z", "timestamp": 1007164800000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Clinical Lymphoma"], "published-print": {"date-parts": [[2001, 12]]}, "DOI": "10.3816/clm.2001.n.021", "type": "journal-article", "created": {"date-parts": [[2008, 9, 11]], "date-time": "2008-09-11T01:09:54Z", "timestamp": 1221095394000}, "page": "155-163", "source": "Crossref", "is-referenced-by-count": 3, "title": ["Diffuse Large-Cell Lymphomas: A Review of Therapy"], "prefix": "10.3816", "volume": "2", "author": [{"given": "John E.", "family": "Godwin", "sequence": "first", "affiliation": []}, {"given": "Richard I.", "family": "Fisher", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["Clinical Lymphoma"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S1526965511701476?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S1526965511701476?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2018, 12, 25]], "date-time": "2018-12-25T22:59:59Z", "timestamp": 1545778799000}, "score": 37.59893, "issued": {"date-parts": [[2001, 12]]}, "references-count": 50, "journal-issue": {"published-print": {"date-parts": [[2001, 12]]}, "issue": "3"}, "alternative-id": ["S1526965511701476"], "URL": "http://dx.doi.org/10.3816/clm.2001.n.021", "ISSN": ["1526-9655"], "issn-type": [{"value": "1526-9655", "type": "print"}], "subject": ["Cancer Research"]}, {"indexed": {"date-parts": [[2019, 11, 21]], "date-time": "2019-11-21T15:37:19Z", "timestamp": 1574350639077}, "reference-count": 24, "publisher": "Elsevier BV", "issue": "1", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2008, 2, 1]], "date-time": "2008-02-01T00:00:00Z", "timestamp": 1201824000000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Cancer Genetics and Cytogenetics"], "published-print": {"date-parts": [[2008, 2]]}, "DOI": "10.1016/j.cancergencyto.2007.10.008", "type": "journal-article", "created": {"date-parts": [[2008, 2, 9]], "date-time": "2008-02-09T12:22:46Z", "timestamp": 1202559766000}, "page": "8-15", "source": "Crossref", "is-referenced-by-count": 75, "title": ["Coordinated expression of microRNA-155 and predicted target genes in diffuse large B-cell lymphoma"], "prefix": "10.1016", "volume": "181", "author": [{"given": "Deepak", "family": "Rai", "sequence": "first", "affiliation": []}, {"given": "Shailaja", "family": "Karanti", "sequence": "additional", "affiliation": []}, {"given": "Inkyung", "family": "Jung", "sequence": "additional", "affiliation": []}, {"given": "Patricia L.M.", "family": "Dahia", "sequence": "additional", "affiliation": []}, {"given": "Ricardo C.T.", "family": "Aguiar", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["Cancer Genetics and Cytogenetics"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S0165460807006917?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S0165460807006917?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2018, 12, 31]], "date-time": "2018-12-31T21:30:04Z", "timestamp": 1546291804000}, "score": 34.39231, "issued": {"date-parts": [[2008, 2]]}, "references-count": 24, "journal-issue": {"published-print": {"date-parts": [[2008, 2]]}, "issue": "1"}, "alternative-id": ["S0165460807006917"], "URL": "http://dx.doi.org/10.1016/j.cancergencyto.2007.10.008", "ISSN": ["0165-4608"], "issn-type": [{"value": "0165-4608", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 23]], "date-time": "2019-11-23T10:58:45Z", "timestamp": 1574506725358}, "reference-count": 5, "publisher": "Elsevier BV", "issue": "4", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2001, 3, 1]], "date-time": "2001-03-01T00:00:00Z", "timestamp": 983404800000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Clinical Lymphoma"], "published-print": {"date-parts": [[2001, 3]]}, "DOI": "10.1016/s1526-9655(11)70168-3", "type": "journal-article", "created": {"date-parts": [[2012, 9, 27]], "date-time": "2012-09-27T21:49:00Z", "timestamp": 1348782540000}, "page": "257-258", "source": "Crossref", "is-referenced-by-count": 1, "title": ["Rituximab Plus CHOP is Superior to CHOP Alone for Aggressive Diffuse Large B-Cell Lymphoma: Interim Results of a GELA Phase III Trial"], "prefix": "10.1016", "volume": "1", "author": [{"given": "Amy I.", "family": "D'Orazio", "sequence": "first", "affiliation": []}], "member": "78", "container-title": ["Clinical Lymphoma"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S1526965511701683?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S1526965511701683?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2018, 11, 20]], "date-time": "2018-11-20T13:28:40Z", "timestamp": 1542720520000}, "score": 30.189285, "issued": {"date-parts": [[2001, 3]]}, "references-count": 5, "journal-issue": {"published-print": {"date-parts": [[2001, 3]]}, "issue": "4"}, "alternative-id": ["S1526965511701683"], "URL": "http://dx.doi.org/10.1016/s1526-9655(11)70168-3", "ISSN": ["1526-9655"], "issn-type": [{"value": "1526-9655", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 12, 1]], "date-time": "2019-12-01T05:31:21Z", "timestamp": 1575178281395}, "reference-count": 24, "publisher": "Elsevier BV", "issue": "7", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2013, 7, 1]], "date-time": "2013-07-01T00:00:00Z", "timestamp": 1372636800000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Human Pathology"], "published-print": {"date-parts": [[2013, 7]]}, "DOI": "10.1016/j.humpath.2012.10.026", "type": "journal-article", "created": {"date-parts": [[2013, 2, 4]], "date-time": "2013-02-04T17:32:23Z", "timestamp": 1359999143000}, "page": "1375-1381", "source": "Crossref", "is-referenced-by-count": 42, "title": ["MYD88 expression and L265P mutation in diffuse large B-cell lymphoma"], "prefix": "10.1016", "volume": "44", "author": [{"given": "Jung-Woo", "family": "Choi", "sequence": "first", "affiliation": []}, {"given": "Younghye", "family": "Kim", "sequence": "additional", "affiliation": []}, {"given": "Ju-Han", "family": "Lee", "sequence": "additional", "affiliation": []}, {"given": "Young-Sik", "family": "Kim", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["Human Pathology"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S0046817712004352?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S0046817712004352?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2018, 10, 19]], "date-time": "2018-10-19T01:25:42Z", "timestamp": 1539912342000}, "score": 30.087313, "issued": {"date-parts": [[2013, 7]]}, "references-count": 24, "journal-issue": {"published-print": {"date-parts": [[2013, 7]]}, "issue": "7"}, "alternative-id": ["S0046817712004352"], "URL": "http://dx.doi.org/10.1016/j.humpath.2012.10.026", "ISSN": ["0046-8177"], "issn-type": [{"value": "0046-8177", "type": "print"}], "subject": ["Pathology and Forensic Medicine"]}, {"indexed": {"date-parts": [[2019, 11, 23]], "date-time": "2019-11-23T00:01:22Z", "timestamp": 1574467282126}, "reference-count": 0, "publisher": "Oxford University Press (OUP)", "issue": "suppl 1", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Annals of Oncology"], "published-print": {"date-parts": [[2000, 1, 1]]}, "DOI": "10.1093/annonc/11.suppl_1.s29", "type": "journal-article", "created": {"date-parts": [[2012, 4, 5]], "date-time": "2012-04-05T22:48:13Z", "timestamp": 1333666093000}, "page": "S29-S33", "source": "Crossref", "is-referenced-by-count": 6, "title": ["Diffuse large-cell lymphoma"], "prefix": "10.1093", "volume": "11", "author": [{"given": "R. I.", "family": "Fisher", "sequence": "first", "affiliation": []}], "member": "286", "container-title": ["Annals of Oncology"], "language": "en", "link": [{"URL": "http://academic.oup.com/annonc/article-pdf/11/suppl_1/S29/7724524/11-suppl_1-S29.pdf", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2017, 8, 22]], "date-time": "2017-08-22T13:22:03Z", "timestamp": 1503408123000}, "score": 29.806505, "issued": {"date-parts": [[2000, 1, 1]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[2000, 1, 1]]}, "issue": "suppl 1"}, "URL": "http://dx.doi.org/10.1093/annonc/11.suppl_1.s29", "ISSN": ["0923-7534", "1569-8041"], "issn-type": [{"value": "0923-7534", "type": "print"}, {"value": "1569-8041", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 12, 4]], "date-time": "2019-12-04T22:19:11Z", "timestamp": 1575497951222}, "reference-count": 0, "publisher": "Ferrata Storti Foundation (Haematologica)", "issue": "7", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Haematologica"], "published-print": {"date-parts": [[2014, 7, 1]]}, "DOI": "10.3324/haematol.2014.107177", "type": "journal-article", "created": {"date-parts": [[2014, 7, 1]], "date-time": "2014-07-01T13:48:31Z", "timestamp": 1404222511000}, "page": "e108-e108", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Ibritumomab tiuxetan plus BEAM in refractory diffuse large B-cell lymphoma"], "prefix": "10.3324", "volume": "99", "author": [{"given": "V.", "family": "Prochazka", "sequence": "first", "affiliation": []}, {"given": "A.", "family": "Hlu\u00a0i", "sequence": "additional", "affiliation": []}], "member": "1856", "published-online": {"date-parts": [[2014, 7, 1]]}, "container-title": ["Haematologica"], "language": "en", "deposited": {"date-parts": [[2014, 7, 31]], "date-time": "2014-07-31T12:53:52Z", "timestamp": 1406811232000}, "score": 29.464912, "issued": {"date-parts": [[2014, 7, 1]]}, "references-count": 0, "journal-issue": {"published-online": {"date-parts": [[2014, 7, 1]]}, "published-print": {"date-parts": [[2014, 7, 1]]}, "issue": "7"}, "URL": "http://dx.doi.org/10.3324/haematol.2014.107177", "ISSN": ["0390-6078", "1592-8721"], "issn-type": [{"value": "0390-6078", "type": "print"}, {"value": "1592-8721", "type": "electronic"}], "subject": ["Hematology"]}, {"indexed": {"date-parts": [[2019, 12, 5]], "date-time": "2019-12-05T07:12:20Z", "timestamp": 1575529940929}, "reference-count": 0, "publisher": "American Society of Hematology", "issue": "21", "content-domain": {"domain": ["ashpublications.org"], "crossmark-restriction": true}, "published-print": {"date-parts": [[2010, 11, 19]]}, "abstract": "<jats:title>Abstract</jats:title>\n               <jats:p>Abstract 5107</jats:p>\n               <jats:sec>\n                  <jats:title>Purpose:</jats:title>\n                  <jats:p>TS is critical for the de novo synthesis of thymidine needed for tumor cell proliferation and DNA damage repair, whereas thymidine kinase 1 (TK1) is key to the salvage pathway providing thymidine recovered from plasma. While TK1 expression has been previously shown to correlate with proliferation in DLBCL, little is known about TS levels in these neoplasms. We hypothesized that, similarly to TK1, TS expression levels associate with increased proliferation and thus may represent a novel therapeutic target in large cell lymphoma.</jats:p>\n               </jats:sec>\n               <jats:sec>\n                  <jats:title>Methods:</jats:title>\n                  <jats:p>To address this hypothesis, we determined the expression of TS in lymph node biopsies from 43 DLBCL patients sequentially enrolled in the study with no pre-selection criteria other than the primary histological diagnosis of lymphoma, and then compared it to TK1 expression. In addition, Ki-67 (MIB1) was included as an established marker of cell proliferation. Pearson correlation along with the correlation coefficient and two-tailed P values were calculated to measure the extent of covariation.</jats:p>\n               </jats:sec>\n               <jats:sec>\n                  <jats:title>Results:</jats:title>\n                  <jats:p>TS expression and both MIB1 and TK1 were significantly correlated with correlation coefficients of 0.43 and 0.65, respectively (95% CI 0.13 to 0.65 and 0.44 to 0.8; P values = 0.006 and &lt;0.0001, respectively). The correlation between TS and MIB1 expression was in fact stronger than between MIB1 and TK1 (P values 0.006 and 0.04, respectively). Mean percent positive cells and standard deviations for MIB1, TS and TK1 were 44.5% (SD=35), 51.8% (SD=33.4), and 44% (SD=28.5), respectively. Despite the general good correlation, however, six patients had relatively high TS levels (defined as % cell staining above the mean for TS) and relatively low TK1 levels (% cell staining below the mean for TK1), while the reverse was true in seven patients. Eight patients had high levels of TK1 and TS with \u2265 70% cells positive for both; seven patients had low levels of both proteins (\u226430% of cells stained).</jats:p>\n               </jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion and Significance:</jats:title>\n                  <jats:p>This is the first report of TS expression in DLBCL. TS is frequently expressed in DLBCL and there is a significant correlation between TS and TK1 or MIB1 expression. Further studies are warranted to determine the correlation between TS or TK1 expression and patient prognosis in comparison to MIB1. Importantly, the common expression of TS in patients with DLBCL indicates that TS may be a suitable target for TS inhibitors (TSIs) in these neoplasms. Preclinical studies are underway to test this hypothesis.</jats:p>\n               </jats:sec>\n               <jats:sec>\n                  <jats:title>Disclosures:</jats:title>\n                  <jats:p>No relevant conflicts of interest to declare.</jats:p>\n               </jats:sec>", "DOI": "10.1182/blood.v116.21.5107.5107", "type": "journal-article", "created": {"date-parts": [[2019, 10, 12]], "date-time": "2019-10-12T16:18:40Z", "timestamp": 1570897120000}, "page": "5107-5107", "update-policy": "http://dx.doi.org/10.1182/blood.2019cm0000", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Thymidylate Synthase (TS) Expression In Diffuse Large B-Cell Lymphoma (DLBCL): Identification of a Potential Therapeutic Target"], "prefix": "10.1182", "volume": "116", "author": [{"given": "Emilian", "family": "Racila", "sequence": "first", "affiliation": [{"name": "Department of Pathology, University of Iowa Hospitals and Clinics, Iowa City, IA, USA,"}]}, {"given": "Sergei I", "family": "Syrbu", "sequence": "additional", "affiliation": [{"name": "Department of Pathology, University of Iowa Hospitals and Clinics, Iowa City, IA, USA,"}]}, {"given": "Michel", "family": "Nasr", "sequence": "additional", "affiliation": [{"name": "Department of Pathology, University of Iowa Hospitals and Clinics, Iowa City, IA, USA,"}]}, {"given": "Malik E.", "family": "Juweid", "sequence": "additional", "affiliation": [{"name": "Dept. of Radiology/Nuclear Med., University of Iowa Hospitals and Clinics, Iowa City, IA, USA"}]}], "member": "234", "container-title": ["Blood"], "language": "en", "link": [{"URL": "https://ashpublications.org/blood/article/116/21/5107/66608/Thymidylate-Synthase-TS-Expression-In-Diffuse", "content-type": "application/pdf", "content-version": "vor", "intended-application": "syndication"}, {"URL": "https://ashpublications.org/blood/article/116/21/5107/66608/Thymidylate-Synthase-TS-Expression-In-Diffuse", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 11, 16]], "date-time": "2019-11-16T14:18:07Z", "timestamp": 1573913887000}, "score": 29.424171, "issued": {"date-parts": [[2010, 11, 19]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[2010, 11, 19]]}, "issue": "21"}, "URL": "http://dx.doi.org/10.1182/blood.v116.21.5107.5107", "ISSN": ["0006-4971", "1528-0020"], "issn-type": [{"value": "0006-4971", "type": "print"}, {"value": "1528-0020", "type": "electronic"}], "subject": ["Immunology", "Cell Biology", "Biochemistry", "Hematology"]}, {"indexed": {"date-parts": [[2019, 11, 21]], "date-time": "2019-11-21T16:53:25Z", "timestamp": 1574355205979}, "publisher-location": "Boston, MA", "reference-count": 61, "publisher": "Springer US", "isbn-type": [{"value": "9780387293455", "type": "print"}, {"value": "9780387293462", "type": "electronic"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "DOI": "10.1007/978-0-387-29346-2_4", "type": "book-chapter", "created": {"date-parts": [[2008, 3, 4]], "date-time": "2008-03-04T06:38:51Z", "timestamp": 1204612731000}, "page": "121-140", "source": "Crossref", "is-referenced-by-count": 3, "title": ["Diffuse Large B-Cell NHL"], "prefix": "10.1007", "author": [{"given": "Jonathan W.", "family": "Friedberg", "sequence": "first", "affiliation": []}, {"given": "Richard I.", "family": "Fisher", "sequence": "additional", "affiliation": []}], "member": "297", "reference": [{"key": "4_CR1", "doi-asserted-by": "crossref", "first-page": "2780", "DOI": "10.1200/JCO.1998.16.8.2780", "volume": "16", "author": "J.O. Armitage", "year": "1998", "unstructured": "Armitage JO, Weisenburger DD: New approach to classifying non-Hodgkin\u2019s lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin\u2019s Lymphoma Classification Project. J Clin Oncol 16:2780\u201395., 1998", "journal-title": "J Clin Oncol"}, {"key": "4_CR2", "doi-asserted-by": "crossref", "first-page": "15", "DOI": "10.3322/canjclin.51.1.15", "volume": "51", "author": "R.T. Greenlee", "year": "2001", "unstructured": "Greenlee RT, Hill-Harmon MB, Murray T, et al: Cancer statistics, 2001. CA Cancer J Clin 51:15\u201336, 2001", "journal-title": "CA Cancer J Clin"}, {"key": "4_CR3", "doi-asserted-by": "publisher", "first-page": "3046", "DOI": "10.1200/JCO.2004.02.104", "volume": "22", "author": "S.T. Hehn", "year": "2004", "unstructured": "Hehn ST, Grogan TM, Miller TP: Utility of fine-needle aspiration as a diagnostic technique in lymphoma. J Clin Oncol 22:3046\u201352, 2004", "journal-title": "J Clin Oncol"}, {"key": "4_CR4", "doi-asserted-by": "crossref", "first-page": "3835", "DOI": "10.1200/JCO.1999.17.12.3835", "volume": "17", "author": "N.L. Harris", "year": "1999", "unstructured": "Harris NL, Jaffe ES, Diebold J, et al: World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 17:3835\u201349., 1999", "journal-title": "J Clin Oncol"}, {"key": "4_CR5", "first-page": "245", "volume": "115", "author": "R.S. Doggett", "year": "1984", "unstructured": "Doggett RS, Wood GS, Horning S, et al: The immunologic characterization of 95 nodal and extranodal diffuse large cell lymphomas in 89 patients. Am J Pathol 115:245\u201352, 1984", "journal-title": "Am J Pathol"}, {"key": "4_CR6", "doi-asserted-by": "publisher", "first-page": "67", "DOI": "10.1016/S0065-230X(08)60456-X", "volume": "42", "author": "H. Stein", "year": "1984", "unstructured": "Stein H, Lennert K, Feller AC, et al: Immunohistological analysis of human lymphoma: correlation of histological and immunological categories. Adv Cancer Res 42:67\u2013147, 1984", "journal-title": "Adv Cancer Res"}, {"key": "4_CR7", "first-page": "1361", "volume": "84", "author": "N.L. Harris", "year": "1994", "unstructured": "Harris NL, Jaffe ES, Stein H, et al: Perspective: A Revised European-American Classificiation of Lymphoid Neoplasm: A Proposal from the International Lymphoma Study Group. Blood 84:1361\u20131392, 1994", "journal-title": "Blood"}, {"key": "4_CR8", "doi-asserted-by": "crossref", "first-page": "1855", "DOI": "10.1200/JCO.2001.19.6.1855", "volume": "19", "author": "K. Besien van", "year": "2001", "unstructured": "van Besien K, Kelta M, Bahaguna P: Primary mediastinal B-cell lymphoma: a review of pathology and management. J Clin Oncol 19:1855\u201364, 2001", "journal-title": "J Clin Oncol"}, {"key": "4_CR9", "doi-asserted-by": "publisher", "first-page": "3871", "DOI": "10.1182/blood-2003-06-1841", "volume": "102", "author": "K.J. Savage", "year": "2003", "unstructured": "Savage KJ, Monti S, Kutok JL, et al: The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood 102:3871\u20139, 2003", "journal-title": "Blood"}, {"key": "4_CR10", "doi-asserted-by": "publisher", "first-page": "173", "DOI": "10.1111/j.1365-2141.2004.05177.x", "volume": "127", "author": "A.J. Ferreri", "year": "2004", "unstructured": "Ferreri AJ, Campo E, Seymour JF, et al: Intravascular lymphoma: clinical presentation, natural history, management and prognostic factors in a series of 38 cases, with special emphasis on the \u2018cutaneous variant\u2019. Br J Haematol 127:173\u201383, 2004", "journal-title": "Br J Haematol"}, {"key": "4_CR11", "first-page": "339", "volume": "87", "author": "V. Ascoli", "year": "2002", "unstructured": "Ascoli V, Lo Coco F, Torelli G, et al: Human herpes virus 8-associated primary effusion lymphoma in HIV\u2014patients: a clinicopidemiologic variant resembling classic Kaposi\u2019s sarcoma. Haematologica 87:339\u201343, 2002", "journal-title": "Haematologica"}, {"key": "4_CR12", "first-page": "244", "volume": "90", "author": "R.D. Gascoyne", "year": "1997", "unstructured": "Gascoyne RD, Adomat SA, Krajewski S, et al: Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin\u2019s lymphoma. Blood 90:244\u201351, 1997", "journal-title": "Blood"}, {"key": "4_CR13", "doi-asserted-by": "publisher", "first-page": "74", "DOI": "10.1056/NEJM199407143310202", "volume": "331", "author": "K. Offit", "year": "1994", "unstructured": "Offit K, LoCoco F, Louie DC, et al: Rearrangement of the bcl-6 gene as a prognostic marker in diffuse large-cell lymphoma. N.Engl.J.Med. 331:74\u201380, 1994", "journal-title": "N.Engl.J.Med."}, {"key": "4_CR14", "doi-asserted-by": "publisher", "first-page": "503", "DOI": "10.1038/35000501", "volume": "403", "author": "A.A. Alizadeh", "year": "2000", "unstructured": "Alizadeh AA, Eisen MB, Davis RE, et al: Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403:503\u201311, 2000", "journal-title": "Nature"}, {"key": "4_CR15", "doi-asserted-by": "publisher", "first-page": "1937", "DOI": "10.1056/NEJMoa012914", "volume": "346", "author": "A. Rosenwald", "year": "2002", "unstructured": "Rosenwald A, Wright G, Chan WC, et al: The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large B-Cell Lymphoma. N.Engl.J.Med. 346:1937\u20131947, 2002", "journal-title": "N.Engl.J.Med."}, {"key": "4_CR16", "doi-asserted-by": "publisher", "first-page": "68", "DOI": "10.1038/nm0102-68", "volume": "8", "author": "M.A. Shipp", "year": "2002", "unstructured": "Shipp MA, Ross KN, Tamayo P, et al: Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 8:68\u201374, 2002", "journal-title": "Nat Med"}, {"key": "4_CR17", "doi-asserted-by": "publisher", "first-page": "1851", "DOI": "10.1182/blood-2004-07-2947", "volume": "105", "author": "S. Monti", "year": "2005", "unstructured": "Monti S, Savage KJ, Kutok JL, et al: Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood 105:1851\u201361, 2005", "journal-title": "Blood"}, {"key": "4_CR18", "doi-asserted-by": "publisher", "first-page": "1828", "DOI": "10.1056/NEJMoa032520", "volume": "350", "author": "I.S. Lossos", "year": "2004", "unstructured": "Lossos IS, Czerwinski DK, Alizadeh AA, et al: Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med 350:1828\u201337, 2004", "journal-title": "N Engl J Med"}, {"key": "4_CR19", "doi-asserted-by": "publisher", "first-page": "438", "DOI": "10.1634/theoncologist.8-5-438", "volume": "8", "author": "J.W. Friedberg", "year": "2003", "unstructured": "Friedberg JW, Chengazi V: PET Scans in the Staging of Lymphoma: Current Status. Oncologist 8:438\u201347, 2003", "journal-title": "Oncologist"}, {"key": "4_CR20", "first-page": "1860", "volume": "31", "author": "P.P. Carbone", "year": "1971", "unstructured": "Carbone PP, Kaplan HS, Musshoff K, et al: Report of the Committee on Hodgkin\u2019s Disease Staging Classification. Cancer Res 31:1860\u20131, 1971", "journal-title": "Cancer Res"}, {"key": "4_CR21", "unstructured": "A predictive model for aggressive non-Hodgkin\u2019s lymphoma. The International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project. N Engl J Med 329:987\u201394, 1993", "DOI": "10.1056/NEJM199309303291402", "doi-asserted-by": "crossref"}, {"key": "4_CR22", "first-page": "181", "volume": "43", "author": "P.S. Schein", "year": "1974", "unstructured": "Schein PS, Chabner BA, Canellos GP, et al: Potential for prolonged disease-free survival following combination chemotherapy of non-Hodgkin\u2019s lymphoma. Blood 43:181\u20139, 1974", "journal-title": "Blood"}, {"key": "4_CR23", "doi-asserted-by": "crossref", "first-page": "1186", "DOI": "10.1200/JCO.1989.7.9.1186", "volume": "7", "author": "S.E. Jones", "year": "1989", "unstructured": "Jones SE, Miller TP, Connors JM: Long-term follow-up and analysis for prognostic factors for patients with limited-stage diffuse large-cell lymphoma treated with initial chemotherapy with or without adjuvant radiotherapy. J Clin Oncol 7:1186\u201391, 1989", "journal-title": "J Clin Oncol"}, {"key": "4_CR24", "doi-asserted-by": "crossref", "first-page": "1179", "DOI": "10.1200/JCO.1989.7.9.1179", "volume": "7", "author": "D.L. Longo", "year": "1989", "unstructured": "Longo DL: Combined modality therapy for localized aggressive lymphoma: enough or too much? J Clin Oncol 7:1179\u201381, 1989", "journal-title": "J Clin Oncol"}, {"key": "4_CR25", "doi-asserted-by": "publisher", "first-page": "21", "DOI": "10.1056/NEJM199807023390104", "volume": "339", "author": "T.P. Miller", "year": "1998", "unstructured": "Miller TP, Dahlberg S, Cassady JR, et al: Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate-and high-grade non-Hodgkin\u2019s lymphoma. N.Engl.J.Med. 339:21\u201326, 1998", "journal-title": "N.Engl.J.Med."}, {"key": "4_CR26", "doi-asserted-by": "publisher", "first-page": "724", "DOI": "10.1182/blood.V98.3.705", "volume": "98", "author": "T.P. Miller", "year": "2001", "unstructured": "Miller TP, LeBlanc M, Spier C, et al: CHOP alone compared to CHOP plus radiotherapy for early stage aggressive non-Hodgkin\u2019s lymphomas: Update of the Southwest Oncology Group (SWOG) randomized trial. Blood 98:724\u20135a, 2001", "journal-title": "Blood"}, {"key": "4_CR27", "doi-asserted-by": "publisher", "first-page": "2982", "DOI": "10.1200/JCO.2004.05.926", "volume": "22", "author": "T.P. Miller", "year": "2004", "unstructured": "Miller TP: The limits of limited stage lymphoma. J Clin Oncol 22:2982\u20134, 2004", "journal-title": "J Clin Oncol"}, {"key": "4_CR28", "doi-asserted-by": "publisher", "first-page": "197", "DOI": "10.1200/JCO.20.1.197", "volume": "20", "author": "T.N. Shenkier", "year": "2002", "unstructured": "Shenkier TN, Voss N, Fairey R, et al: Brief chemotherapy and involved-region irradiation for limited-stage diffuse large-cell lymphoma: an 18-year experience from the British Columbia Cancer Agency. J Clin Oncol 20:197\u2013204, 2002", "journal-title": "J Clin Oncol"}, {"key": "4_CR29", "doi-asserted-by": "publisher", "first-page": "3032", "DOI": "10.1200/JCO.2004.06.088", "volume": "22", "author": "S.J. Horning", "year": "2004", "unstructured": "Horning SJ, Weller E, Kim K, et al: Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin\u2019s lymphoma: Eastern Cooperative Oncology Group study 1484. J Clin Oncol 22:3032\u20138, 2004", "journal-title": "J Clin Oncol"}, {"key": "4_CR30", "doi-asserted-by": "publisher", "first-page": "1197", "DOI": "10.1056/NEJMoa042040", "volume": "352", "author": "F. Reyes", "year": "2005", "unstructured": "Reyes F, Lepage E, Ganem G, et al: ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N Engl J Med 352:1197\u2013205, 2005", "journal-title": "N Engl J Med"}, {"key": "4_CR31", "first-page": "92a", "volume": "100", "author": "G. Fillet", "year": "2002", "unstructured": "Fillet G, Bonnet C, Mournier N, et al: Radiotherapy is unnecessary in elderly patients with localized aggressive non Hodgkin\u2019s lymphoma: Results of the GELA LNH 93\u20134 study. Blood 100:92a, 2002", "journal-title": "Blood"}, {"key": "4_CR32", "first-page": "48a", "volume": "104", "author": "T.P. Miller", "year": "2004", "unstructured": "Miller TP, Unger JM, Spier C, et al: Effect of adding rituximab to three cycles of CHOP plus involved field radiotherapy for limited-stage aggressive diffuse B cell lymphoma, SWOG 0014. Blood 104:48a, 2004", "journal-title": "Blood"}, {"key": "4_CR33", "doi-asserted-by": "publisher", "first-page": "303", "DOI": "10.1054/bjoc.2000.1566", "volume": "84", "author": "A. Messori", "year": "2001", "unstructured": "Messori A, Vaiani M, Trippoli S, et al: Survival in patients with intermediate or high grade non-Hodgkin\u2019s lymphoma: meta-analysis of randomized studies comparing third generation regimens with CHOP. Br J Cancer 84:303\u20137, 2001", "journal-title": "Br J Cancer"}, {"key": "4_CR34", "doi-asserted-by": "publisher", "first-page": "1342", "DOI": "10.1056/NEJM199211053271903", "volume": "327", "author": "L.I. Gordon", "year": "1992", "unstructured": "Gordon LI, Harrington D, Andersen J, et al: Comparison of a Second-Generation Combination Chemotherapeutic Regimen (m-BACOD) with a Standard Regimen (CHOP) for Advanced Diffuse Non-Hodgkin\u2019s Lymphoma. N.Engl.J.Med. 327:1342\u20131349, 1992", "journal-title": "N.Engl.J.Med."}, {"key": "4_CR35", "doi-asserted-by": "publisher", "first-page": "1002", "DOI": "10.1056/NEJM199304083281404", "volume": "328", "author": "R.I. Fisher", "year": "1993", "unstructured": "Fisher RI, Gaynor ER, Dahlberg S, et al: Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin\u2019s lymphoma. N Engl J Med 328:1002\u20136, 1993", "journal-title": "N Engl J Med"}, {"key": "4_CR36", "doi-asserted-by": "crossref", "first-page": "389", "DOI": "10.1200/JCO.2001.19.2.389", "volume": "19", "author": "J.M. Vose", "year": "2001", "unstructured": "Vose JM, Link BK, Grossbard ML, et al: Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin\u2019s lymphoma. J Clin Oncol 19:389\u201397, 2001", "journal-title": "J Clin Oncol"}, {"key": "4_CR37", "doi-asserted-by": "publisher", "first-page": "235", "DOI": "10.1056/NEJMoa011795", "volume": "346", "author": "B. Coiffier", "year": "2002", "unstructured": "Coiffier B, Lepage E, Briere J, et al: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235\u201342, 2002", "journal-title": "N Engl J Med"}, {"key": "4_CR38", "doi-asserted-by": "publisher", "first-page": "4279", "DOI": "10.1182/blood-2002-11-3442", "volume": "101", "author": "N. Mounier", "year": "2003", "unstructured": "Mounier N, Briere J, Gisselbrecht C, et al: Rituximab plus CHOP (R-CHOP) overcomes bcl-2\u2014associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 101:4279\u201384, 2003", "journal-title": "Blood"}, {"key": "4_CR39", "first-page": "6a", "volume": "102", "author": "T.M. Haberman", "year": "2003", "unstructured": "Haberman TM, Weller EA, Morrison VA, et al: Phase III trial of rituximab-CHOP vs. CHOP with a second randomization to maintenance rituximab or observation in patients 60 years of age and older with diffuse large B cell lymphoma. Blood 102:6a, 2003", "journal-title": "Blood"}, {"key": "4_CR40", "first-page": "48a", "volume": "104", "author": "M. Pfreundschuh", "year": "2004", "unstructured": "Pfreundschuh M, Truemper L, Gill D, et al: First analysis of the completed Mabthera international trial in young patients with low-risk diffuse large B cell lymphoma: addition of rituximab to a CHOP-like regimen significantly improves outcome of all patients with the identification of a very favorable subgroup with IPI=0 and no bulky disease. Blood 104:48a, 2004", "journal-title": "Blood"}, {"key": "4_CR41", "doi-asserted-by": "publisher", "first-page": "2466", "DOI": "10.1200/JCO.2003.06.137", "volume": "21", "author": "D.W. Blayney", "year": "2003", "unstructured": "Blayney DW, LeBlanc ML, Grogan T, et al: Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate-and high-grade lymphoma: a phase II study of the Southwest Oncology Group (SWOG 9349). J Clin Oncol 21:2466\u201373, 2003", "journal-title": "J Clin Oncol"}, {"key": "4_CR42", "doi-asserted-by": "publisher", "first-page": "634", "DOI": "10.1182/blood-2003-06-2095", "volume": "104", "author": "M. Pfreundschuh", "year": "2004", "unstructured": "Pfreundschuh M, Trumper L, Kloess M, et al: Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 104:634\u201341, 2004", "journal-title": "Blood"}, {"key": "4_CR43", "doi-asserted-by": "publisher", "first-page": "626", "DOI": "10.1182/blood-2003-06-2094", "volume": "104", "author": "M. Pfreundschuh", "year": "2004", "unstructured": "Pfreundschuh M, Trumper L, Kloess M, et al: Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood 104:626\u201333, 2004", "journal-title": "Blood"}, {"key": "4_CR44", "doi-asserted-by": "publisher", "first-page": "1540", "DOI": "10.1056/NEJM199512073332305", "volume": "333", "author": "T. Philip", "year": "1995", "unstructured": "Philip T, Guglielmi C, Hagenbeek A, et al: Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin\u2019s lymphoma. N Engl J Med 333:1540\u20135, 1995", "journal-title": "N Engl J Med"}, {"key": "4_CR45", "doi-asserted-by": "crossref", "first-page": "3025", "DOI": "10.1200/JCO.2000.18.16.3025", "volume": "18", "author": "C. Haioun", "year": "2000", "unstructured": "Haioun C, Lepage E, Gisselbrecht C, et al: Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin\u2019s lymphoma: Final analysis of the Prospective LNH87-2 Protocol-A Groupe d\u2019Etude des Lymphomes de l\u2019Adulte Study. J.Clin.Oncol. 18:3025\u20133030, 2000", "journal-title": "J.Clin.Oncol."}, {"key": "4_CR46", "doi-asserted-by": "crossref", "first-page": "2796", "DOI": "10.1200/JCO.1998.16.8.2796", "volume": "16", "author": "G. Santini", "year": "1998", "unstructured": "Santini G, Salvagno L, Leoni P, et al: VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin\u2019s lymphoma: results of a prospective randomized trial by the non-Hodgkin\u2019s lymphoma cooperative study group. J.Clin.Oncol. 16:2796\u20132802, 1998", "journal-title": "J.Clin.Oncol."}, {"key": "4_CR47", "doi-asserted-by": "publisher", "first-page": "22", "DOI": "10.1093/jnci/93.1.22", "volume": "93", "author": "H.C. Kluin-Nelemans", "year": "2000", "unstructured": "Kluin-Nelemans HC, Zagonel V, Anastasopoulou A, et al: Standard Chemotherapy with or without High-Dose Chemotherapy for Aggressive Non-Hodgkin\u2019s Lymphoma: Randomized Phase III EORTC Study. J.Nat.Cancer Inst. 93:22\u201330, 2000", "journal-title": "J.Nat.Cancer Inst."}, {"key": "4_CR48", "unstructured": "Kaiser U, Uebelacker I, Abel U, et al: A Randomized Study to Evaluate The Use of High-Dose Therapy As Part Of Primary Treatment for \u2018Aggressive\u2019 Lymphoma. J.Clin.Oncol., 2002", "DOI": "10.1200/JCO.2002.07.075", "doi-asserted-by": "crossref"}, {"key": "4_CR49", "doi-asserted-by": "publisher", "first-page": "1290", "DOI": "10.1056/NEJM199705013361804", "volume": "336", "author": "A.M. Gianni", "year": "1997", "unstructured": "Gianni AM, Bregni M, Siena S, et al: High dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N.Engl.J.Med. 336:1290\u20131297, 1997", "journal-title": "N.Engl.J.Med."}, {"key": "4_CR50", "doi-asserted-by": "publisher", "first-page": "2472", "DOI": "10.1200/JCO.2002.02.125", "volume": "20", "author": "C. Gisselbrecht", "year": "2002", "unstructured": "Gisselbrecht C, Lepage E, Molina T, et al: Shortened First-Line High-Dose Chemotherapy For Patients With Poor-Risk Aggressive Lymphoma. J.Clin.Oncol. 20:2472\u20132479, 2002", "journal-title": "J.Clin.Oncol."}, {"key": "4_CR51", "doi-asserted-by": "publisher", "first-page": "1045", "DOI": "10.1056/NEJM199504203321601", "volume": "332", "author": "L.F. Verdonck", "year": "1995", "unstructured": "Verdonck LF, van Putten WLJ, Hagenbeek A, et al: Comparison of CHOP Chemotherapy with Autologous Bone Marrow Transplantation for Slowly Responding Patients with Aggressive Non-Hodgkin\u2019s Lymphoma. N.Engl.J.Med. 332:1045\u20131051, 1995", "journal-title": "N.Engl.J.Med."}, {"key": "4_CR52", "doi-asserted-by": "publisher", "first-page": "1287", "DOI": "10.1056/NEJMoa031770", "volume": "350", "author": "N. Milpied", "year": "2004", "unstructured": "Milpied N, Deconinck E, Gaillard F, et al: Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med 350:1287\u201395, 2004", "journal-title": "N Engl J Med"}, {"key": "4_CR53", "doi-asserted-by": "crossref", "first-page": "3128", "DOI": "10.1200/JCO.1999.17.10.3128", "volume": "17", "author": "J.W. Friedberg", "year": "1999", "unstructured": "Friedberg JW, Neuberg D, Stone RM, et al: Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin\u2019s lymphoma. J Clin Oncol 17:3128\u201335, 1999", "journal-title": "J Clin Oncol"}, {"key": "4_CR54", "doi-asserted-by": "publisher", "first-page": "2208", "DOI": "10.1200/JCO.2005.05.158", "volume": "23", "author": "J.R. Brown", "year": "2005", "unstructured": "Brown JR, Yeckes H, Friedberg JW, et al: Increasing Incidence of Late Second Malignancies After Conditioning With Cyclophosphamide and Total-Body Irradiation and Autologous Bone Marrow Transplantation for Non-Hodgkin\u2019s Lymphoma. J Clin Oncol 23:2208\u201314, 2005", "journal-title": "J Clin Oncol"}, {"key": "4_CR55", "doi-asserted-by": "crossref", "first-page": "423", "DOI": "10.1200/JCO.1999.17.1.423", "volume": "17", "author": "M.A. Shipp", "year": "1999", "unstructured": "Shipp MA, Abeloff MD, Antman KH, et al: International consensus conference on high-dose therapy with hematopoietic stem cell transplantation in aggressive non-Hodgkin\u2019s lymphomas: Report of the jury. J.Clin.Oncol. 17:423\u2013429, 1999", "journal-title": "J.Clin.Oncol."}, {"key": "4_CR56", "first-page": "1927", "volume": "92", "author": "B. Coiffier", "year": "1998", "unstructured": "Coiffier B, Haioun C, Ketterer N, et al: Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 92:1927\u201332, 1998", "journal-title": "Blood"}, {"key": "4_CR57", "first-page": "41a", "volume": "104", "author": "F. Morschhauser", "year": "2004", "unstructured": "Morschhauser F, Huglo D, Martinelli G, et al: Yttrium-90 Ibribumomab tiuxetan for patients with relapsed/refractroy diffuse large B cell lymphoma not appropriate for autologous stem cell transplantation: results of an open-label phase II trial. Blood 104:41a, 2004", "journal-title": "Blood"}, {"key": "4_CR58", "doi-asserted-by": "publisher", "first-page": "3684", "DOI": "10.1182/blood-2003-11-3911", "volume": "103", "author": "T. Kewalramani", "year": "2004", "unstructured": "Kewalramani T, Zelenetz AD, Nimer SD, et al: Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood 103:3684\u20138, 2004", "journal-title": "Blood"}, {"key": "4_CR59", "doi-asserted-by": "publisher", "first-page": "153", "DOI": "10.1111/j.1365-2141.2004.05251.x", "volume": "128", "author": "K.S. Peggs", "year": "2005", "unstructured": "Peggs KS, Mackinnon S, Linch DC: The role of allogeneic transplantation in non-Hodgkin\u2019s lymphoma. Br J Haematol 128:153\u201368, 2005", "journal-title": "Br J Haematol"}, {"key": "4_CR60", "doi-asserted-by": "publisher", "first-page": "2419", "DOI": "10.1200/JCO.2004.09.092", "volume": "22", "author": "M.P. Escalon", "year": "2004", "unstructured": "Escalon MP, Champlin RE, Saliba RM, et al: Nonmyeloablative allogeneic hematopoietic transplantation: a promising salvage therapy for patients with non-Hodgkin\u2019s lymphoma whose disease has failed a prior autologous transplantation. J Clin Oncol 22:2419\u201323, 2004", "journal-title": "J Clin Oncol"}, {"key": "4_CR61", "doi-asserted-by": "publisher", "first-page": "5297", "DOI": "10.1158/1078-0432.CCR-04-0922", "volume": "10", "author": "J.W. Friedberg", "year": "2004", "unstructured": "Friedberg JW: Developing new monoclonal antibodies for aggressive lymphoma: a challenging road in the rituximab era. Clin Cancer Res 10:5297\u20138, 2004", "journal-title": "Clin Cancer Res"}], "container-title": ["Hodgkin\u2019s and Non-Hodgkin\u2019s Lymphoma", "Cancer Treatment and Research"], "link": [{"URL": "http://www.springerlink.com/index/pdf/10.1007/978-0-387-29346-2_4", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 5, 8]], "date-time": "2019-05-08T16:12:37Z", "timestamp": 1557331957000}, "score": 29.027075, "issued": {"date-parts": [[null]]}, "ISBN": ["9780387293455", "9780387293462"], "references-count": 61, "URL": "http://dx.doi.org/10.1007/978-0-387-29346-2_4", "relation": {"cites": []}}, {"indexed": {"date-parts": [[2019, 12, 17]], "date-time": "2019-12-17T14:41:24Z", "timestamp": 1576593684891}, "reference-count": 0, "publisher": "Ovid Technologies (Wolters Kluwer Health)", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["HemaSphere"], "published-print": {"date-parts": [[2019, 6]]}, "DOI": "10.1097/01.hs9.0000561148.15666.da", "type": "journal-article", "created": {"date-parts": [[2019, 6, 17]], "date-time": "2019-06-17T13:56:18Z", "timestamp": 1560779778000}, "page": "313", "source": "Crossref", "is-referenced-by-count": 0, "title": ["CLINICAL IMPACT OF PROGNOSTIC NUTRITIONAL INDEX IN DIFFUSE LARGE B CELL LYMPHOMA"], "prefix": "10.1097", "volume": "3", "author": [{"given": "S.-I.", "family": "Go", "sequence": "first", "affiliation": []}, {"given": "G.-W.", "family": "Lee", "sequence": "additional", "affiliation": []}], "member": "276", "container-title": ["HemaSphere"], "language": "en", "link": [{"URL": "http://journals.lww.com/10.1097/01.HS9.0000561148.15666.da", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 12, 17]], "date-time": "2019-12-17T14:12:56Z", "timestamp": 1576591976000}, "score": 29.027075, "subtitle": ["PF716"], "issued": {"date-parts": [[2019, 6]]}, "references-count": 0, "URL": "http://dx.doi.org/10.1097/01.hs9.0000561148.15666.da", "ISSN": ["2572-9241"], "issn-type": [{"value": "2572-9241", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 12, 17]], "date-time": "2019-12-17T14:41:04Z", "timestamp": 1576593664205}, "reference-count": 0, "publisher": "Ovid Technologies (Wolters Kluwer Health)", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["HemaSphere"], "published-print": {"date-parts": [[2019, 6]]}, "DOI": "10.1097/01.hs9.0000562620.32098.e1", "type": "journal-article", "created": {"date-parts": [[2019, 6, 17]], "date-time": "2019-06-17T14:13:46Z", "timestamp": 1560780826000}, "page": "490-491", "source": "Crossref", "is-referenced-by-count": 0, "title": ["PROGNOSTIC SIGNIFICANCE OF SAMHD1 EXPRESSION IN DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)"], "prefix": "10.1097", "volume": "3", "author": [{"given": "I.", "family": "Xagoraris", "sequence": "first", "affiliation": []}, {"given": "N.", "family": "Herold", "sequence": "additional", "affiliation": []}, {"given": "B.", "family": "Sander", "sequence": "additional", "affiliation": []}, {"given": "Ekstr\u00f6m K.", "family": "Smedby", "sequence": "additional", "affiliation": []}, {"given": "G.", "family": "Rassidakis", "sequence": "additional", "affiliation": []}], "member": "276", "container-title": ["HemaSphere"], "language": "en", "link": [{"URL": "http://journals.lww.com/10.1097/01.HS9.0000562620.32098.e1", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 12, 17]], "date-time": "2019-12-17T14:23:59Z", "timestamp": 1576592639000}, "score": 28.730461, "subtitle": ["PS1082"], "issued": {"date-parts": [[2019, 6]]}, "references-count": 0, "URL": "http://dx.doi.org/10.1097/01.hs9.0000562620.32098.e1", "ISSN": ["2572-9241"], "issn-type": [{"value": "2572-9241", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 22]], "date-time": "2019-11-22T10:40:48Z", "timestamp": 1574419248403}, "reference-count": 0, "publisher": "BMJ", "issue": "nov11 1", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Case Reports"], "published-print": {"date-parts": [[2011, 11, 15]]}, "DOI": "10.1136/bcr.07.2011.4430", "type": "journal-article", "created": {"date-parts": [[2011, 11, 16]], "date-time": "2011-11-16T12:54:32Z", "timestamp": 1321448072000}, "page": "bcr0720114430-bcr0720114430", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Diffuse large B cell lymphoma: cutaneous manifestation"], "prefix": "10.1136", "volume": "2011", "author": [{"given": "R.", "family": "Sajjan", "sequence": "first", "affiliation": []}, {"given": "A.", "family": "Haroon", "sequence": "additional", "affiliation": []}, {"given": "Z.", "family": "Saad", "sequence": "additional", "affiliation": []}, {"given": "I.", "family": "Kayani", "sequence": "additional", "affiliation": []}], "member": "239", "published-online": {"date-parts": [[2011, 11, 15]]}, "container-title": ["Case Reports"], "language": "en", "link": [{"URL": "https://syndication.highwire.org/content/doi/10.1136/bcr.07.2011.4430", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2016, 12, 23]], "date-time": "2016-12-23T22:54:33Z", "timestamp": 1482533673000}, "score": 28.469261, "issued": {"date-parts": [[2011, 11, 15]]}, "references-count": 0, "journal-issue": {"published-online": {"date-parts": [[2011, 11, 15]]}, "published-print": {"date-parts": [[2011, 12, 8]]}, "issue": "nov11 1"}, "URL": "http://dx.doi.org/10.1136/bcr.07.2011.4430", "ISSN": ["1757-790X"], "issn-type": [{"value": "1757-790X", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 24]], "date-time": "2019-11-24T03:50:31Z", "timestamp": 1574567431458}, "reference-count": 27, "publisher": "Springer Science and Business Media LLC", "issue": "2", "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2014, 12, 12]], "date-time": "2014-12-12T00:00:00Z", "timestamp": 1418342400000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": ["link.springer.com"], "crossmark-restriction": false}, "short-container-title": ["Int J Hematol"], "published-print": {"date-parts": [[2015, 2]]}, "DOI": "10.1007/s12185-014-1719-3", "type": "journal-article", "created": {"date-parts": [[2014, 12, 11]], "date-time": "2014-12-11T08:18:22Z", "timestamp": 1418285902000}, "page": "140-147", "update-policy": "http://dx.doi.org/10.1007/springer_crossmark_policy", "source": "Crossref", "is-referenced-by-count": 4, "title": ["High Ki-67 expression in involved bone marrow predicts worse clinical outcome in diffuse large B cell lymphoma patients treated with R-CHOP therapy"], "prefix": "10.1007", "volume": "101", "author": [{"given": "Moo-Kon", "family": "Song", "sequence": "first", "affiliation": []}, {"given": "Joo-Seop", "family": "Chung", "sequence": "additional", "affiliation": []}, {"given": "Je-Jung", "family": "Lee", "sequence": "additional", "affiliation": []}, {"given": "Deok-Hwan", "family": "Yang", "sequence": "additional", "affiliation": []}, {"given": "In-Suk", "family": "Kim", "sequence": "additional", "affiliation": []}, {"given": "Dong-Hoon", "family": "Shin", "sequence": "additional", "affiliation": []}, {"given": "Ho-Jin", "family": "Shin", "sequence": "additional", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2014, 12, 12]]}, "reference": [{"key": "1719_CR1", "doi-asserted-by": "crossref", "first-page": "473", "DOI": "10.1111/j.1600-0609.2006.00644.x", "volume": "76", "author": "J Campbell", "year": "2006", "unstructured": "Campbell J, Seymour JF, Matthews J, Wolf M, Stone J, Juneja S. The prognostic impact of bone marrow involvement in patients with diffuse large cell lymphoma varies according to the degree of infiltration and presence of discordant marrow involvement. Eur J Haematol. 2006;76:473\u201380.", "journal-title": "Eur J Haematol"}, {"key": "1719_CR2", "doi-asserted-by": "crossref", "first-page": "1278", "DOI": "10.1182/blood-2007-01-070300", "volume": "110", "author": "R Chung", "year": "2007", "unstructured": "Chung R, Lai R, Wei P, Lee J, Hanson J, Belch AR, et al. Concordant but not discordant bone marrow involvement in diffuse large B-cell lymphoma predicts a poor clinical outcome independent of the International Prognostic Index. Blood. 2007;110:1278\u201382.", "journal-title": "Blood"}, {"key": "1719_CR3", "doi-asserted-by": "crossref", "first-page": "305", "DOI": "10.1093/ajcp/101.3.305", "volume": "101", "author": "GF Hodges", "year": "1994", "unstructured": "Hodges GF, Lenhardt TM, Cotelingam JD. Bone marrow involvement in large-cell lymphoma. Prognostic implications of discordant disease. Am J Clin Pathol. 1994;101:305\u201311.", "journal-title": "Am J Clin Pathol"}, {"key": "1719_CR4", "doi-asserted-by": "crossref", "first-page": "236", "DOI": "10.1200/JCO.1991.9.2.236", "volume": "9", "author": "LE Robertson", "year": "1991", "unstructured": "Robertson LE, Redman JR, Butler JJ, Osborne BM, Velasquez WS, McLaughlin P, et al. Discordant bone marrow involvement in diffuse large-cell lymphoma: a distinct clinical-pathologic entity associated with a continuous risk of relapse. J Clin Oncol. 1991;9:236\u201342.", "journal-title": "J Clin Oncol"}, {"key": "1719_CR5", "doi-asserted-by": "crossref", "first-page": "1336", "DOI": "10.1200/JCO.1995.13.6.1336", "volume": "13", "author": "Y Yan", "year": "1995", "unstructured": "Yan Y, Chan WC, Weisenburger DD, Anderson JR, Bast MA, Vose JM, et al. Clinical and prognostic significance of bone marrow involvement in patients with diffuse aggressive B-cell lymphoma. J Clin Oncol. 1995;13:1336\u201342.", "journal-title": "J Clin Oncol"}, {"key": "1719_CR6", "doi-asserted-by": "crossref", "first-page": "1879", "DOI": "10.1002/1097-0142(19891101)64:9<1879::AID-CNCR2820640921>3.0.CO;2-D", "volume": "64", "author": "DE Fisher", "year": "1989", "unstructured": "Fisher DE, Jacobson JO, Ault KA, Harris NL. Diffuse large cell lymphoma with discordant bone marrow histology. Clinical features and biological implications. Cancer. 1989;64:1879\u201387.", "journal-title": "Cancer"}, {"key": "1719_CR7", "doi-asserted-by": "crossref", "first-page": "503", "DOI": "10.1038/35000501", "volume": "403", "author": "AA Alizadeh", "year": "2000", "unstructured": "Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503\u201311.", "journal-title": "Nature"}, {"key": "1719_CR8", "doi-asserted-by": "crossref", "first-page": "1937", "DOI": "10.1056/NEJMoa012914", "volume": "346", "author": "A Rosenwald", "year": "2002", "unstructured": "Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:1937\u201347.", "journal-title": "N Engl J Med"}, {"key": "1719_CR9", "doi-asserted-by": "crossref", "first-page": "68", "DOI": "10.1038/nm0102-68", "volume": "8", "author": "MA Shipp", "year": "2002", "unstructured": "Shipp MA, Ross KN, Tamayo P, Weng AP, Kutok JL, Aguiar RC, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med. 2002;8:68\u201374.", "journal-title": "Nat Med"}, {"key": "1719_CR10", "doi-asserted-by": "crossref", "first-page": "275", "DOI": "10.1182/blood-2003-05-1545", "volume": "103", "author": "CP Hans", "year": "2004", "unstructured": "Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103:275\u201382.", "journal-title": "Blood"}, {"key": "1719_CR11", "doi-asserted-by": "crossref", "first-page": "1828", "DOI": "10.1056/NEJMoa032520", "volume": "350", "author": "IS Lossos", "year": "2004", "unstructured": "Lossos IS, Czerwinski DK, Alizadeh AA, Wechser MA, Tibshirani R, Botstein D, et al. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med. 2004;350:1828\u201337.", "journal-title": "N Engl J Med"}, {"key": "1719_CR12", "doi-asserted-by": "crossref", "first-page": "4930", "DOI": "10.1182/blood-2006-09-047068", "volume": "109", "author": "H Nyman", "year": "2007", "unstructured": "Nyman H, Adde M, Karjalainen-Lindsberg ML, Taskinen M, Berglund M, Amini RM, et al. Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy. Blood. 2007;109:4930\u20135.", "journal-title": "Blood"}, {"key": "1719_CR13", "doi-asserted-by": "crossref", "first-page": "4279", "DOI": "10.1182/blood-2002-11-3442", "volume": "101", "author": "N Mounier", "year": "2003", "unstructured": "Mounier N, Briere J, Gisselbrecht C, Emile JF, Lederlin P, Sebban C, et al. Rituximab plus CHOP (R-CHOP) overcomes Bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood. 2003;101:4279\u201384.", "journal-title": "Blood"}, {"key": "1719_CR14", "doi-asserted-by": "crossref", "first-page": "1102", "DOI": "10.1080/10428190701344881", "volume": "48", "author": "KS Wilson", "year": "2007", "unstructured": "Wilson KS, Sehn LH, Berry B, Chhanabhai M, Fitzgerald CA, Gill KK, et al. CHOP-R therapy overcomes the adverse prognostic influence of BCL-2 expression in diffuse large B-cell lymphoma. Leuk Lymphoma. 2007;48:1102\u20139.", "journal-title": "Leuk Lymphoma"}, {"key": "1719_CR15", "doi-asserted-by": "crossref", "first-page": "1244", "DOI": "10.1200/JCO.1999.17.4.1244", "volume": "17", "author": "BD Cheson", "year": "1999", "unstructured": "Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17:1244\u201353.", "journal-title": "J Clin Oncol"}, {"key": "1719_CR16", "doi-asserted-by": "crossref", "first-page": "420", "DOI": "10.1136/jclinpath-2012-201158", "volume": "66", "author": "H Shim", "year": "2013", "unstructured": "Shim H, Oh JI, Park SH, Jang S, Park CJ, Huh J, et al. Prognostic impact of concordant and discordant cytomorphology of bone marrow involvement in patients with diffuse, large, B-cell lymphoma treated with R-CHOP. J Clin Pathol. 2013;66:420\u20135.", "journal-title": "J Clin Pathol"}, {"key": "1719_CR17", "doi-asserted-by": "crossref", "first-page": "235", "DOI": "10.1056/NEJMoa011795", "volume": "346", "author": "B Coiffier", "year": "2002", "unstructured": "Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235\u201342.", "journal-title": "N Engl J Med"}, {"key": "1719_CR18", "doi-asserted-by": "crossref", "first-page": "4117", "DOI": "10.1200/JCO.2005.09.131", "volume": "23", "author": "P Feugier", "year": "2005", "unstructured": "Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Ferm\u00e9 C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte. J Clin Oncol. 2005;23:4117\u201326.", "journal-title": "J Clin Oncol"}, {"key": "1719_CR19", "doi-asserted-by": "crossref", "first-page": "3121", "DOI": "10.1200/JCO.2005.05.1003", "volume": "24", "author": "TM Habermann", "year": "2006", "unstructured": "Habermann TM, Weller EA, Morrison VA, Gascoyne RD, Cassileth PA, Cohn JB, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 2006;24:3121\u20137.", "journal-title": "J Clin Oncol"}, {"key": "1719_CR20", "doi-asserted-by": "crossref", "first-page": "1452", "DOI": "10.1200/JCO.2010.33.3419", "volume": "29", "author": "LH Sehn", "year": "2011", "unstructured": "Sehn LH, Scott DW, Chhanabhai M, Berry B, Ruskova A, Berkahn L, et al. Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol. 2011;29:1452\u20137.", "journal-title": "J Clin Oncol"}, {"key": "1719_CR21", "first-page": "1710", "volume": "133", "author": "J Gerdes", "year": "1984", "unstructured": "Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol. 1984;133:1710\u20135.", "journal-title": "J Immunol"}, {"key": "1719_CR22", "doi-asserted-by": "crossref", "first-page": "15", "DOI": "10.1385/MO:18:1:15", "volume": "18", "author": "M Llanos", "year": "2001", "unstructured": "Llanos M, Alvarez-Arg\u00fcelles H, Alem\u00e1n R, Oramas J, Diaz-Flores L, Batista N. Prognostic significance of Ki-67 nuclear proliferative antigen, bcl-2 protein, and p53 expression in follicular and diffuse large B-cell lymphoma. Med Oncol. 2001;18:15\u201322.", "journal-title": "Med Oncol"}, {"key": "1719_CR23", "doi-asserted-by": "crossref", "first-page": "495", "DOI": "10.1080/028418699432040", "volume": "38", "author": "H Holte", "year": "1999", "unstructured": "Holte H, Suo Z, Smeland EB, Kval\u00f8y S, Langholm R, Stokke T. Prognostic value of lymphoma-specific S-phase fraction compared with that of other cell proliferation markers. Acta Oncol. 1999;38:495\u2013503.", "journal-title": "Acta Oncol"}, {"key": "1719_CR24", "first-page": "487", "volume": "17", "author": "A Kalogeraki", "year": "1997", "unstructured": "Kalogeraki A, Tzardi M, Panagiotides I, Koutsoubi K, Bolioti S, Rontogianni D, et al. MIB1 (Ki-67) expression in non-Hodgkin\u2019s lymphomas. Anticancer Res. 1997;17:487\u201391.", "journal-title": "Anticancer Res"}, {"key": "1719_CR25", "first-page": "601", "volume": "89", "author": "WH Wilson", "year": "1997", "unstructured": "Wilson WH, Teruya-Feldstein J, Fest T, Harris C, Steinberg SM, Jaffe ES, et al. Relationship of p53, bcl-2, and tumor proliferation to clinical drug resistance in non-Hodgkin\u2019s lymphomas. Blood. 1997;89:601\u20139.", "journal-title": "Blood"}, {"key": "1719_CR26", "first-page": "1460", "volume": "83", "author": "TP Miller", "year": "1994", "unstructured": "Miller TP, Grogan TM, Dahlberg S, Spier CM, Braziel RM, Banks PM, et al. Prognostic significance of the Ki-67-associated proliferative antigen in aggressive non-Hodgkin\u2019s lymphomas: a prospective Southwest Oncology Group trial. Blood. 1994;83:1460\u20136.", "journal-title": "Blood"}, {"key": "1719_CR27", "doi-asserted-by": "crossref", "first-page": "667", "DOI": "10.1111/j.1440-1827.2004.01678.x", "volume": "54", "author": "B Saito", "year": "2004", "unstructured": "Saito B, Shiozawa E, Yamochi-Onizuka T, Adachi D, Nakamaki T, Tomoyasu S, et al. Efficacy of rituximab plus chemotherapy in follicular lymphoma depends on Ki-67 expression. Pathol Int. 2004;54:667\u201374.", "journal-title": "Pathol Int"}], "container-title": ["International Journal of Hematology"], "language": "en", "link": [{"URL": "http://link.springer.com/content/pdf/10.1007/s12185-014-1719-3.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://link.springer.com/article/10.1007/s12185-014-1719-3/fulltext.html", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://link.springer.com/content/pdf/10.1007/s12185-014-1719-3", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 8, 18]], "date-time": "2019-08-18T09:59:45Z", "timestamp": 1566122385000}, "score": 27.799414, "issued": {"date-parts": [[2014, 12, 12]]}, "references-count": 27, "journal-issue": {"published-print": {"date-parts": [[2015, 2]]}, "issue": "2"}, "alternative-id": ["1719"], "URL": "http://dx.doi.org/10.1007/s12185-014-1719-3", "relation": {"cites": []}, "ISSN": ["0925-5710", "1865-3774"], "issn-type": [{"value": "0925-5710", "type": "print"}, {"value": "1865-3774", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 26]], "date-time": "2019-11-26T16:08:37Z", "timestamp": 1574784517555}, "reference-count": 11, "publisher": "Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation", "issue": "1", "license": [{"URL": "http://creativecommons.org/licenses/by-nc/4.0", "start": {"date-parts": [[2016, 1, 1]], "date-time": "2016-01-01T00:00:00Z", "timestamp": 1451606400000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Blood Res"], "published-print": {"date-parts": [[2016]]}, "DOI": "10.5045/br.2016.51.1.61", "type": "journal-article", "created": {"date-parts": [[2016, 4, 12]], "date-time": "2016-04-12T01:31:47Z", "timestamp": 1460424707000}, "page": "61", "source": "Crossref", "is-referenced-by-count": 1, "title": ["A case ofPneumocystis jirovecipneumonia after bendamustine-based chemotherapy for refractory diffuse large B-cell lymphoma"], "prefix": "10.5045", "volume": "51", "author": [{"given": "Jeonghoon", "family": "Ha", "sequence": "first", "affiliation": [{"name": "Division of Hematology-Oncology, Department of Internal Medicine, Yeouido St Mary's Hospital, The Catholic University of Korea, College of Medicine, Seoul, Korea."}]}, {"given": "Yunhwa", "family": "Jung", "sequence": "additional", "affiliation": [{"name": "Division of Hematology-Oncology, Department of Internal Medicine, Yeouido St Mary's Hospital, The Catholic University of Korea, College of Medicine, Seoul, Korea."}]}, {"given": "Yunduk", "family": "Jung", "sequence": "additional", "affiliation": [{"name": "Division of Hematology-Oncology, Department of Internal Medicine, Yeouido St Mary's Hospital, The Catholic University of Korea, College of Medicine, Seoul, Korea."}]}, {"given": "Sanbin", "family": "Lee", "sequence": "additional", "affiliation": [{"name": "Division of Hematology-Oncology, Department of Internal Medicine, Yeouido St Mary's Hospital, The Catholic University of Korea, College of Medicine, Seoul, Korea."}]}, {"given": "Yoonseo", "family": "Lee", "sequence": "additional", "affiliation": [{"name": "Division of Hematology-Oncology, Department of Internal Medicine, Yeouido St Mary's Hospital, The Catholic University of Korea, College of Medicine, Seoul, Korea."}]}, {"given": "Insook", "family": "Woo", "sequence": "additional", "affiliation": [{"name": "Division of Hematology-Oncology, Department of Internal Medicine, Yeouido St Mary's Hospital, The Catholic University of Korea, College of Medicine, Seoul, Korea."}]}], "member": "2988", "container-title": ["Blood Research"], "language": "en", "link": [{"URL": "https://synapse.koreamed.org/DOIx.php?id=10.5045/br.2016.51.1.61", "content-type": "unspecified", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://synapse.koreamed.org/pdf/10.5045/br.2016.51.1.61", "content-type": "unspecified", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://synapse.koreamed.org/DOIx.php?id=10.5045/br.2016.51.1.61", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2018, 10, 8]], "date-time": "2018-10-08T01:49:15Z", "timestamp": 1538963355000}, "score": 27.561228, "issued": {"date-parts": [[2016]]}, "references-count": 11, "journal-issue": {"published-print": {"date-parts": [[2016]]}, "issue": "1"}, "URL": "http://dx.doi.org/10.5045/br.2016.51.1.61", "ISSN": ["2287-979X", "2288-0011"], "issn-type": [{"value": "2287-979X", "type": "print"}, {"value": "2288-0011", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 12, 5]], "date-time": "2019-12-05T07:38:15Z", "timestamp": 1575531495765}, "reference-count": 0, "publisher": "American Society of Hematology", "issue": "Supplement 1", "content-domain": {"domain": ["ashpublications.org"], "crossmark-restriction": true}, "published-print": {"date-parts": [[2018, 11, 29]]}, "abstract": "<jats:title>Abstract</jats:title>\n               <jats:p>Background:</jats:p>\n               <jats:p>Treatment outcomes for diffuse large B-cell lymphoma (DLBCL) have improved with the addition of rituximab to cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). However, up to 40% of patients with DLBCL do not achieve durable remission and develop relapsed or refractory disease. The standard treatment for relapsed or refractory patients is salvage chemotherapy followed by autologous hematopoietic stem cell transplantation (ASCT). But long-term survival outcome is still unsatisfactory. So, we investigated survival outcome and prognostic factors for patients with relapsed or refractory DLBCL who received salvage chemotherapy followed by ASCT.</jats:p>\n               <jats:p>Methods:</jats:p>\n               <jats:p>We retrospectively identified 117 patients with relapsed or refractory DLBCL who received salvage chemotherapy and ASCT at Asan Medical Center between January 2008 and December 2017. Survival outcomes were estimated using the Kaplan-Meier method and compared using the log-rank test. The Cox proportional hazards regression was used to analyses prognostic factor for survival outcomes.</jats:p>\n               <jats:p>Results:</jats:p>\n               <jats:p>The median age at ASCT was 52 years (range, 17 to 69 years) with the study group comprised of 47 women (40.2%) and 70 men (59.8%). Sixty-one patients (52.1%) received etoposide, cytarabine, cisplatin, and methylprednisolone (ESHAP) salvage chemotherapy; 12 (10.3%) vincristine, methotrexate, ifosfamide, etoposide, cytarabine, cyclophosphamide, doxorubicin, and dexamethasone (BNHL); 11 (9.4%) ifosfamide, carboplatin, etoposide, and dexamethasone (ICE-D); and the remaining 33 (28.2%) other regimens. The ASCT conditioning regimens were thiotepa, busulfan, and cyclophosphamide (TBC) in 27 patients (23.1%), busulfan, etoposide, and cyclophosphamide (BuCyE) in 68 (58.1%), and other regimes in 22 (18.8%). After receiving ASCT, 86 patients (73.5%) achieved complete response; 17 (14.5%) partial response; and 13 (11.1%) stable disease or progressive disease. At a median follow-up of 14.1 months (range, 0.2 to 117.6 months), 81 patients had an event and 64 patients had died.</jats:p>\n               <jats:p>The two-year progression-free survival (PFS) and overall survival (OS) for all study patients were 30.3% and 48.2%, respectively. A univariate analysis showed the performance status at ASCT (HR 1.7, 95%CI 1.0 to 2.8, p=0.04), stage at ASCT (HR 2.7, 95%CI 1.5 to 4.9, p&lt;0.01), beta-2 microglobulin (B2MG) at ASCT (HR 2.0, 95%CI 1.2 to 3.3, p&lt;0.01), age-adjusted International Prognostic Index (AA-IPI) at ASCT (HR 2.8, 95%CI 1.6-5.0, p&lt;0.01), number of previous chemotherapy (HR 2.4, 95%CI 1.3 to 4.3, p&lt;0.01), and achievement of complete response after salvage chemotherapy (HR 1.8, 95%CI 1.1 to 3.1, p=0.02) as significant prognostic factors for ASCT. When B2MG at ASCT was divided into high and low group base on 2.4 ug/mL, two-year PFS was 36.7% and 19.9% (HR 1.8, 95%CI 1.1 to 2.8, p=0.01), respectively, two-year OS was 57.7% and 31.2% (HR 2.0, 95%CI 1.2 to 3.4, p&lt;0.01), respectively. Kaplan Meier survival analysis was shown in figure 1. A multivariate analysis revealed B2MG at ASCT (HR 1.9, 95%CI 1.1 to 3.2, p=0.02), AA-IPI at ASCT (HR 2.7, 95%CI 1.4 to 5.2, p&lt;0.01), and number of previous chemotherapy (HR 2.2, 95%CI 1.2 to 4.0, p=0.01) as significant factors for the OS.</jats:p>\n               <jats:p>Conclusions:</jats:p>\n               <jats:p>In this study, B2MG at ASCT, AA-IPI at ASCT, and number of previous chemotherapy were independent predictors of overall survival in relapsed or refractory DLBCL undergoing salvage chemotherapy followed by ASCT. To our knowledge, this is the first report showing that B2MG at ASCT is an independent prognostic factor for overall survival after ASCT and we suggest that further studies are needed.</jats:p>\n               <jats:p />\n               <jats:sec>\n                  <jats:title>Disclosures</jats:title>\n                  <jats:p>No relevant conflicts of interest to declare.</jats:p>\n               </jats:sec>", "DOI": "10.1182/blood-2018-99-120334", "type": "journal-article", "created": {"date-parts": [[2019, 10, 14]], "date-time": "2019-10-14T17:42:47Z", "timestamp": 1571074967000}, "page": "5755-5755", "update-policy": "http://dx.doi.org/10.1182/blood.2019cm0000", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Serum Beta-2 Microglobulin Predicts the Survival Outcome after Autologous Stem Cell Transplantation in Relapse or Refractory Diffuse Large B Cell Lymphoma"], "prefix": "10.1182", "volume": "132", "author": [{"given": "Hyeun-Su", "family": "Im", "sequence": "first", "affiliation": [{"name": "Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea, Seoul, Korea, Republic of (South)"}]}, {"given": "Jung Yong", "family": "Hong", "sequence": "additional", "affiliation": [{"name": "Department of Oncology, Asan Medical Center, University of Ulsan College of MedicineAsan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea, Seoul, Korea, Republic of (South)"}]}, {"given": "Dok Hyun", "family": "Yoon", "sequence": "additional", "affiliation": [{"name": "Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea, Seoul, Korea, Republic of (South)"}]}, {"given": "Shin", "family": "Kim", "sequence": "additional", "affiliation": [{"name": "Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea, Seoul, Korea, Republic of (South)"}]}, {"given": "Jung Sun", "family": "Park", "sequence": "additional", "affiliation": [{"name": "Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea, Seoul, Korea, Republic of (South)"}]}, {"given": "Sang Wook", "family": "Lee", "sequence": "additional", "affiliation": [{"name": "Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of (South)"}]}, {"given": "Chan-Sik", "family": "Park", "sequence": "additional", "affiliation": [{"name": "Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea, Seoul, Korea, Republic of (South)"}]}, {"given": "Jin-Sook", "family": "Ryu", "sequence": "additional", "affiliation": [{"name": "Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of (South)"}]}, {"given": "Jooryung", "family": "Huh", "sequence": "additional", "affiliation": [{"name": "Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of (South)"}]}, {"given": "Cheolwon", "family": "Suh", "sequence": "additional", "affiliation": [{"name": "Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of (South)"}]}], "member": "234", "container-title": ["Blood"], "language": "en", "link": [{"URL": "https://ashpublications.org/blood/article/132/Supplement%201/5755/263095/Serum-Beta2-Microglobulin-Predicts-the-Survival", "content-type": "application/pdf", "content-version": "vor", "intended-application": "syndication"}, {"URL": "https://ashpublications.org/blood/article/132/Supplement%201/5755/263095/Serum-Beta2-Microglobulin-Predicts-the-Survival", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 11, 15]], "date-time": "2019-11-15T18:58:23Z", "timestamp": 1573844303000}, "score": 27.415148, "issued": {"date-parts": [[2018, 11, 29]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[2018, 11, 29]]}, "issue": "Supplement 1"}, "URL": "http://dx.doi.org/10.1182/blood-2018-99-120334", "ISSN": ["0006-4971", "1528-0020"], "issn-type": [{"value": "0006-4971", "type": "print"}, {"value": "1528-0020", "type": "electronic"}], "subject": ["Immunology", "Cell Biology", "Biochemistry", "Hematology"]}, {"indexed": {"date-parts": [[2019, 11, 23]], "date-time": "2019-11-23T06:58:33Z", "timestamp": 1574492313688}, "reference-count": 30, "publisher": "Informa UK Limited", "issue": "2", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Leukemia & Lymphoma"], "published-print": {"date-parts": [[2011, 2]]}, "DOI": "10.3109/10428194.2010.542261", "type": "journal-article", "created": {"date-parts": [[2011, 2, 1]], "date-time": "2011-02-01T12:19:15Z", "timestamp": 1296562755000}, "page": "205-213", "source": "Crossref", "is-referenced-by-count": 10, "title": ["Hypoxia-associated protein expression in primary central nervous system diffuse large B-cell lymphoma: does it predict prognosis?"], "prefix": "10.1080", "volume": "52", "author": [{"given": "Jung A.", "family": "Kim", "sequence": "first", "affiliation": []}, {"given": "Seok Jin", "family": "kim", "sequence": "additional", "affiliation": []}, {"given": "In-Gu", "family": "Do", "sequence": "additional", "affiliation": []}, {"given": "Juyoun", "family": "Jin", "sequence": "additional", "affiliation": []}, {"given": "Do-Hyun", "family": "Nam", "sequence": "additional", "affiliation": []}, {"given": "Young Hyeh", "family": "Ko", "sequence": "additional", "affiliation": []}, {"given": "Kihyun", "family": "Kim", "sequence": "additional", "affiliation": []}, {"given": "Won", "family": "Seog kim", "sequence": "additional", "affiliation": []}], "member": "301", "published-online": {"date-parts": [[2011, 2]]}, "reference": [{"key": "CIT0001", "author": "Semenza GL", "volume": "88", "first-page": "1474", "year": "2000", "journal-title": "J Appl Physiol", "DOI": "10.1152/jappl.2000.88.4.1474", "doi-asserted-by": "crossref"}, {"key": "CIT0002", "DOI": "10.1016/j.semcancer.2008.11.009", "doi-asserted-by": "publisher"}, {"key": "CIT0003", "DOI": "10.1093/jnci/93.4.266", "doi-asserted-by": "publisher"}, {"key": "CIT0004", "DOI": "10.1038/nrc704", "doi-asserted-by": "publisher"}, {"key": "CIT0005", "DOI": "10.1016/j.lungcan.2005.03.036", "doi-asserted-by": "publisher"}, {"key": "CIT0006", "DOI": "10.1093/jjco/hym121", "doi-asserted-by": "publisher"}, {"key": "CIT0007", "author": "Hockel M", "volume": "56", "first-page": "4509", "year": "1996", "journal-title": "Cancer Res"}, {"key": "CIT0008", "DOI": "10.1016/S0360-3016(02)02848-1", "doi-asserted-by": "publisher"}, {"key": "CIT0009", "DOI": "10.1046/j.1365-2559.2002.01357.x", "doi-asserted-by": "publisher"}, {"key": "CIT0010", "DOI": "10.1016/j.prp.2008.07.007", "doi-asserted-by": "publisher"}, {"key": "CIT0011", "DOI": "10.1002/hon.861", "doi-asserted-by": "publisher"}, {"key": "CIT0012", "DOI": "10.1200/JCO.2009.24.1893", "doi-asserted-by": "publisher"}, {"key": "CIT0013", "DOI": "10.1007/978-1-4615-4863-8_2", "doi-asserted-by": "publisher"}, {"key": "CIT0014", "DOI": "10.1080/10428190902964776", "doi-asserted-by": "publisher"}, {"key": "CIT0015", "DOI": "10.1200/JCO.2005.13.524", "doi-asserted-by": "publisher"}, {"key": "CIT0016", "DOI": "10.1016/0197-2456(96)00075-X", "doi-asserted-by": "publisher"}, {"key": "CIT0017", "DOI": "10.1038/nrc1187", "doi-asserted-by": "publisher"}, {"key": "CIT0018", "DOI": "10.1074/jbc.274.10.6519", "doi-asserted-by": "publisher"}, {"key": "CIT0019", "DOI": "10.1016/S0360-3016(02)02815-8", "doi-asserted-by": "publisher"}, {"key": "CIT0020", "DOI": "10.1054/bjoc.2000.1357", "doi-asserted-by": "publisher"}, {"key": "CIT0021", "DOI": "10.1038/sj.bjc.6605026", "doi-asserted-by": "publisher"}, {"key": "CIT0022", "DOI": "10.1080/00313020802579318", "doi-asserted-by": "publisher"}, {"key": "CIT0023", "DOI": "10.1002/1097-0142(20010801)92:3<634::AID-CNCR1364>3.0.CO;2-X", "doi-asserted-by": "publisher"}, {"key": "CIT0024", "DOI": "10.1016/j.ejca.2003.10.024", "doi-asserted-by": "publisher"}, {"key": "CIT0025", "DOI": "10.1016/j.nucmedbio.2008.11.009", "doi-asserted-by": "publisher"}, {"key": "CIT0026", "DOI": "10.3727/096504009787721177", "doi-asserted-by": "publisher"}, {"key": "CIT0027", "DOI": "10.1097/MNM.0b013e32832cc295", "doi-asserted-by": "publisher"}, {"key": "CIT0028", "author": "Bellamy WT", "volume": "59", "first-page": "728", "year": "1999", "journal-title": "Cancer Res"}, {"key": "CIT0029", "author": "Foekens JA", "volume": "61", "first-page": "5407", "year": "2001", "journal-title": "Cancer Res"}, {"key": "CIT0030", "DOI": "10.1038/labinvest.3700697", "doi-asserted-by": "publisher"}], "container-title": ["Leukemia & Lymphoma"], "language": "en", "link": [{"URL": "http://www.tandfonline.com/doi/pdf/10.3109/10428194.2010.542261", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 6, 8]], "date-time": "2019-06-08T07:54:21Z", "timestamp": 1559980461000}, "score": 27.379503, "issued": {"date-parts": [[2011, 2]]}, "references-count": 30, "journal-issue": {"published-online": {"date-parts": [[2011, 1, 24]]}, "published-print": {"date-parts": [[2011, 2]]}, "issue": "2"}, "alternative-id": ["10.3109/10428194.2010.542261"], "URL": "http://dx.doi.org/10.3109/10428194.2010.542261", "relation": {"cites": []}, "ISSN": ["1042-8194", "1029-2403"], "issn-type": [{"value": "1042-8194", "type": "print"}, {"value": "1029-2403", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 27]], "date-time": "2019-11-27T13:40:18Z", "timestamp": 1574862018272}, "reference-count": 0, "publisher": "Oxford University Press (OUP)", "issue": "suppl_10", "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2017, 11, 1]]}, "DOI": "10.1093/annonc/mdx664.016", "type": "journal-article", "created": {"date-parts": [[2017, 11, 22]], "date-time": "2017-11-22T11:47:24Z", "timestamp": 1511351244000}, "source": "Crossref", "is-referenced-by-count": 0, "title": ["334PThe white blood cell differential predict treatment response in diffuse large B cell lymphoma"], "prefix": "10.1093", "volume": "28", "author": [{"given": "T S", "family": "Hastuti", "sequence": "first", "affiliation": []}, {"given": "I", "family": "Wijaya", "sequence": "additional", "affiliation": []}, {"given": "A", "family": "Oehadian", "sequence": "additional", "affiliation": []}], "member": "286", "published-online": {"date-parts": [[2017, 11, 22]]}, "container-title": ["Annals of Oncology"], "language": "en", "link": [{"URL": "http://academic.oup.com/annonc/article-pdf/28/suppl_10/mdx664.016/21936715/mdx664.016.pdf", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2017, 11, 22]], "date-time": "2017-11-22T11:47:24Z", "timestamp": 1511351244000}, "score": 26.957859, "issued": {"date-parts": [[2017, 11, 1]]}, "references-count": 0, "journal-issue": {"published-online": {"date-parts": [[2017, 11, 22]]}, "published-print": {"date-parts": [[2017, 11, 1]]}, "issue": "suppl_10"}, "URL": "http://dx.doi.org/10.1093/annonc/mdx664.016", "ISSN": ["0923-7534", "1569-8041"], "issn-type": [{"value": "0923-7534", "type": "print"}, {"value": "1569-8041", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 12, 5]], "date-time": "2019-12-05T07:14:28Z", "timestamp": 1575530068391}, "reference-count": 0, "publisher": "American Society of Hematology", "issue": "21", "content-domain": {"domain": ["ashpublications.org"], "crossmark-restriction": true}, "published-print": {"date-parts": [[2011, 11, 18]]}, "abstract": "<jats:title>Abstract</jats:title>\n               <jats:p>Abstract 1595</jats:p>\n               <jats:sec>\n                  <jats:title>Background:</jats:title>\n                  <jats:p>The self-reported Quality of life (QoL) assessment has been widely used as an endpoint for clinical trials along with traditional endpoints of response and survival because the QoL can provide the health-related information, and it should be considered another parameter to estimate the efficacy of treatment. However, there is growing evidence that the QoL assessment can be used as a prognostic factor in cancer patients. Thus, the prognostic value of baseline QoL was reported in several different types of cancers independent of other clinical prognostic factors. Considering the performance status of patients is an important prognostic factor in lymphoma, the assessment of QoL at diagnosis might be an informative tool for predicting treatment outcome of lymphoma. However, few data exists regarding the prognostic relevance of baseline QoL in patients with lymphoma. Thus, we evaluated the prognostic impact of baseline QoL on the outcome of patients with diffuse large B-cell lymphoma (DLBCL), the most common subtype of non-Hodgkin lymphoma.</jats:p>\n               </jats:sec>\n               <jats:sec>\n                  <jats:title>Methods:</jats:title>\n                  <jats:p>The Samsung Medical Center Lymphoma Cohort Study (SMCLCS) is a prospective cohort study registering patients diagnosed with Hodgkin and non-Hodgkin lymphoma at the Samsung Medical Center (NCT00822731). All patients completed the version 3.0 of the European Organization for Research and Treatment of Cancer (EORTC) Core Questionnaire (QLQ-C30) after they provided written inform consents. Among patients registered in the SMCLCS, we analyzed the baseline QoL and clinical data of 263 patients consecutively diagnosed with DLBCL between September 2008 and February 2011. Primary CNS lymphoma was excluded, thus, all patients were treated with rituximab-CHOP. We made a prognostic model according to the scores of three items: (1) Global health status representing general health condition, (2) Functional scale representing physical function, (3) Symptom scales representing symptoms and signs. Each item was counted as one point if the score of each item was higher than 50. Thus, patients were classified as good (3 points), moderate (2 points) and poor QoL (score =0 or 1) groups. The QoL scores of patients with marginal zone B-cell lymphoma (MZL, n = 110) were used as a control.</jats:p>\n               </jats:sec>\n               <jats:sec>\n                  <jats:title>Results:</jats:title>\n                  <jats:p>The median score of Global health status was 50 (range 0\u2013100) while the median scores of Functional and Symptom scales were 78.4 (24.1\u2013100.0) and 79 (25.9\u2013100.0), respectively in patients with DLBCL. These scores were significantly lower than a control group, MZL (P &lt; 0.05). When patients were categorized into three groups, the good and moderate QoL groups accounted for 43.0% (n = 113) and 41.1% (n = 108) of patients, respectively. The proportion of poor QoL group of DLBCL was 16.0% (n = 42), and it was higher than that of MZL (2.7%). When the QoL at diagnosis was compared with other clinical factors, the poor QoL was significantly associated with poor ECOG performance status (\u2264 grade 2) whereas age older than 60 years was not significantly related with the poor QoL. The clinical factors representing high tumor burden such as elevated serum LDH, the number of extranodal involvement and Ann Arbor stage were significantly associated with the QoL model, thus, patients with high tumor burden showed poor QoL (P &lt; 0.05). In consistent with this, patients with high or high-intermediate International Prognostic Index showed worse QoL scores than low or low-intermediate risk group. The frequency of treatment-related mortality was significantly higher in patients belonging to moderate and poor QoL groups than good QoL group (P &lt; 0.05). As a result, more than 20% of the moderate or poor QoL group failed to complete the planned treatment schedule of rituximab-CHOP while only 10% of patients of the good QoL group could not finish the treatment. As a result, the overall survival of the good QoL group was significantly better than moderate and poor QoL groups (p &lt; 0.05). This risk stratification based on the baseline QoL assessment was independently prognostic for overall survival in the multivariate analysis after controlling for International Prognostic Index.</jats:p>\n               </jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion:</jats:title>\n                  <jats:p>The baseline quality of life assessed with the EORTC QLQ-C30 is significantly associated with high tumor burden and worse overall survival of DLBCL. Thus, this prospective result suggests that the it may become a feasible prognostic factor in patients with DLBCL.</jats:p>\n               </jats:sec>\n               <jats:sec>\n                  <jats:title>Disclosures:</jats:title>\n                  <jats:p>No relevant conflicts of interest to declare.</jats:p>\n               </jats:sec>", "DOI": "10.1182/blood.v118.21.1595.1595", "type": "journal-article", "created": {"date-parts": [[2019, 10, 12]], "date-time": "2019-10-12T20:29:41Z", "timestamp": 1570912181000}, "page": "1595-1595", "update-policy": "http://dx.doi.org/10.1182/blood.2019cm0000", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Baseline Quality of Life Assessed with the EORTC QLQ-C30 Predicts the Treatment Outcome of Patients with Diffuse Large B-Cell Lymphoma: Results of a Prospective Cohort Study"], "prefix": "10.1182", "volume": "118", "author": [{"given": "Hyun Ae", "family": "Jung", "sequence": "first", "affiliation": [{"name": "Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea,"}]}, {"given": "Seok Jin", "family": "Kim", "sequence": "additional", "affiliation": [{"name": "Medicine, Samsung Med. Ctr., Seoul, South Korea,"}]}, {"given": "Jun Ho", "family": "Jang", "sequence": "additional", "affiliation": [{"name": "Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea,"}]}, {"given": "Kihyun", "family": "Kim", "sequence": "additional", "affiliation": [{"name": "Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, Division of Hematology-Oncology, Seoul, South Korea,"}]}, {"given": "Chul Won", "family": "Jung", "sequence": "additional", "affiliation": [{"name": "Medicine, Samsung Medical Center, Seoul, South Korea,"}]}, {"given": "Won Seog", "family": "Kim", "sequence": "additional", "affiliation": [{"name": "Medicine, Sungkyunkwan University School of Medicine, Seoul, South Korea"}]}], "member": "234", "container-title": ["Blood"], "language": "en", "link": [{"URL": "https://ashpublications.org/blood/article/118/21/1595/139895/Baseline-Quality-of-Life-Assessed-with-the-EORTC", "content-type": "application/pdf", "content-version": "vor", "intended-application": "syndication"}, {"URL": "https://ashpublications.org/blood/article/118/21/1595/139895/Baseline-Quality-of-Life-Assessed-with-the-EORTC", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 11, 19]], "date-time": "2019-11-19T13:19:09Z", "timestamp": 1574169549000}, "score": 26.749506, "issued": {"date-parts": [[2011, 11, 18]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[2011, 11, 18]]}, "issue": "21"}, "URL": "http://dx.doi.org/10.1182/blood.v118.21.1595.1595", "ISSN": ["0006-4971", "1528-0020"], "issn-type": [{"value": "0006-4971", "type": "print"}, {"value": "1528-0020", "type": "electronic"}], "subject": ["Immunology", "Cell Biology", "Biochemistry", "Hematology"]}, {"indexed": {"date-parts": [[2019, 11, 22]], "date-time": "2019-11-22T07:35:15Z", "timestamp": 1574408115898}, "reference-count": 5, "publisher": "Wiley", "license": [{"URL": "http://doi.wiley.com/10.1002/tdm_license_1.1", "start": {"date-parts": [[2015, 9, 1]], "date-time": "2015-09-01T00:00:00Z", "timestamp": 1441065600000}, "delay-in-days": 1421, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2012, 5]]}, "DOI": "10.1111/j.1439-0272.2011.01236.x", "type": "journal-article", "created": {"date-parts": [[2011, 10, 12]], "date-time": "2011-10-12T03:40:53Z", "timestamp": 1318390853000}, "page": "845-847", "source": "Crossref", "is-referenced-by-count": 5, "title": ["Primary diffuse large B-cell testicular lymphoma: magnetic resonance imaging findings"], "prefix": "10.1111", "volume": "44", "author": [{"given": "A. C.", "family": "Tsili", "sequence": "first", "affiliation": []}, {"given": "M. I.", "family": "Argyropoulou", "sequence": "additional", "affiliation": []}, {"given": "D.", "family": "Giannakis", "sequence": "additional", "affiliation": []}, {"given": "N.", "family": "Sofikitis", "sequence": "additional", "affiliation": []}, {"given": "K.", "family": "Tsampoulas", "sequence": "additional", "affiliation": []}], "member": "311", "published-online": {"date-parts": [[2011, 10, 11]]}, "reference": [{"key": "10.1111/j.1439-0272.2011.01236.x-BIB1|cit1", "doi-asserted-by": "crossref", "first-page": "610", "DOI": "10.1007/s00261-005-0115-0", "article-title": "Imaging diagnosis of testicular lymphoma", "volume": "31", "author": "Liu", "year": "2006", "journal-title": "Abdom Imaging"}, {"key": "10.1111/j.1439-0272.2011.01236.x-BIB2|cit2", "doi-asserted-by": "crossref", "first-page": "419", "DOI": "10.1016/S0090-4295(01)01579-5", "article-title": "Magnetic resonance imaging of scrotal diseases: when it makes the difference", "volume": "59", "author": "Muglia", "year": "2002", "journal-title": "Urology"}, {"key": "10.1111/j.1439-0272.2011.01236.x-BIB3|cit3", "doi-asserted-by": "crossref", "first-page": "W331", "DOI": "10.2214/AJR.07.2267", "article-title": "MRI in the histologic characterization of testicular neoplasms", "volume": "189", "author": "Tsili", "year": "2007", "journal-title": "AJR Am J Roentgenol"}, {"key": "10.1111/j.1439-0272.2011.01236.x-BIB4|cit4", "doi-asserted-by": "crossref", "first-page": "189", "DOI": "10.1148/radiographics.22.1.g02ja14189", "article-title": "From the archives of the AFIP: tumors and tumorlike lesions of the testis: radiologic-pathologic correlation", "volume": "22", "author": "Woodward", "year": "2002", "journal-title": "Radiographics"}, {"key": "10.1111/j.1439-0272.2011.01236.x-BIB5|cit5", "doi-asserted-by": "crossref", "first-page": "243", "DOI": "10.1148/rg.251045041", "article-title": "Best cases from the AFIP: primary diffuse large B-cell lymphoma of the epididymis and testis", "volume": "25", "author": "Zicherman", "year": "2005", "journal-title": "Radiographics"}], "container-title": ["Andrologia"], "language": "en", "link": [{"URL": "https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1439-0272.2011.01236.x", "content-type": "unspecified", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2017, 6, 20]], "date-time": "2017-06-20T07:46:55Z", "timestamp": 1497944815000}, "score": 26.739412, "subtitle": ["Primary testicular lymphoma"], "issued": {"date-parts": [[2011, 10, 11]]}, "references-count": 5, "URL": "http://dx.doi.org/10.1111/j.1439-0272.2011.01236.x", "relation": {"cites": []}, "ISSN": ["0303-4569"], "issn-type": [{"value": "0303-4569", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 27]], "date-time": "2019-11-27T04:03:02Z", "timestamp": 1574827382246}, "reference-count": 53, "publisher": "F1000 Research Ltd", "license": [{"URL": "http://creativecommons.org/licenses/by/4.0/", "start": {"date-parts": [[2016, 8, 8]], "date-time": "2016-08-08T00:00:00Z", "timestamp": 1470614400000}, "delay-in-days": 0, "content-version": "unspecified"}], "content-domain": {"domain": ["f1000research.com"], "crossmark-restriction": false}, "short-container-title": ["F1000Res"], "abstract": "<ns4:p>Various strategies have been implemented to improve the outcomes of diffuse large B-cell lymphoma (DLBCL). In recent years, remarkable advances have been achieved, based on the discovery of cell-of-origin in DLBCL and on more effective targeted agents. This commentary will summarize recent updates on the evolution of frontline therapies for DLBCL, focusing on the upcoming promising frontline chemotherapy platforms and on activated B-cell subtype DLBCL and double-hit DLBCL.</ns4:p>", "DOI": "10.12688/f1000research.8790.1", "type": "journal-article", "created": {"date-parts": [[2016, 8, 8]], "date-time": "2016-08-08T13:30:12Z", "timestamp": 1470663012000}, "page": "1933", "update-policy": "http://dx.doi.org/10.12688/f1000research.crossmark-policy", "source": "Crossref", "is-referenced-by-count": 3, "title": ["Evolution of frontline treatment of diffuse large B-cell lymphoma: a brief review and recent update"], "prefix": "10.12688", "volume": "5", "author": [{"given": "Jung Yong", "family": "Hong", "sequence": "first", "affiliation": []}, {"given": "Cheolwon", "family": "Suh", "sequence": "additional", "affiliation": []}, {"given": "Won Seog", "family": "Kim", "sequence": "additional", "affiliation": []}], "member": "2560", "published-online": {"date-parts": [[2016, 8, 8]]}, "reference": [{"key": "ref-1", "doi-asserted-by": "publisher", "first-page": "235-42", "DOI": "10.1056/NEJMoa011795", "article-title": "CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.", "volume": "346", "author": "B Coiffier", "year": "2002", "journal-title": "N Engl J Med."}, {"key": "ref-2", "doi-asserted-by": "publisher", "first-page": "379-91", "DOI": "10.1016/S1470-2045(06)70664-7", "article-title": "CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.", "volume": "7", "author": "M Pfreundschuh", "year": "2006", "journal-title": "Lancet Oncol."}, {"key": "ref-3", "doi-asserted-by": "publisher", "first-page": "498-505", "DOI": "10.1182/asheducation-2011.1.498", "article-title": "Relapsed/refractory diffuse large B-cell lymphoma.", "volume": "2011", "author": "J Friedberg", "year": "2011", "journal-title": "Hematology Am Soc Hematol Educ Program."}, {"key": "ref-4", "doi-asserted-by": "publisher", "first-page": "1858-67", "DOI": "10.1016/S0140-6736(11)61040-4", "article-title": "Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial.", "volume": "378", "author": "C R\u00e9cher", "year": "2011", "journal-title": "Lancet."}, {"key": "ref-5", "doi-asserted-by": "publisher", "first-page": "2717-24", "DOI": "10.1200/JCO.2007.13.1391", "article-title": "Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers.", "volume": "26", "author": "W Wilson", "year": "2008", "journal-title": "J Clin Oncol."}, {"key": "ref-6", "doi-asserted-by": "publisher", "first-page": "758-65", "DOI": "10.3324/haematol.2011.056531", "article-title": "A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype.", "volume": "97", "author": "W Wilson", "year": "2012", "journal-title": "Haematologica."}, {"key": "ref-7", "doi-asserted-by": "publisher", "first-page": "188-98", "DOI": "10.1111/bjh.13273", "article-title": "Long-term follow-up of dose-adjusted EPOCH plus rituximab (DA-EPOCH-R) in untreated patients with poor prognosis large B-cell lymphoma. A phase II study conducted by the Spanish PETHEMA Group.", "volume": "169", "author": "N Purroy", "year": "2015", "journal-title": "Br J Haematol."}, {"key": "ref-8", "doi-asserted-by": "publisher", "first-page": "1800-6", "DOI": "10.1093/annonc/mdu208", "article-title": "Optimization of rituximab for the treatment of DLBCL (I): dose-dense rituximab in the DENSE-R-CHOP-14 trial of the DSHNHL.", "volume": "25", "author": "N Murawski", "year": "2014", "journal-title": "Ann Oncol."}, {"key": "ref-9", "doi-asserted-by": "publisher", "first-page": "4127-33", "DOI": "10.1200/JCO.2013.54.6861", "article-title": "Optimization of rituximab for the treatment of diffuse large B-cell lymphoma (II): extended rituximab exposure time in the SMARTE-R-CHOP-14 trial of the german high-grade non-Hodgkin lymphoma study group.", "volume": "32", "author": "M Pfreundschuh", "year": "2014", "journal-title": "J Clin Oncol."}, {"key": "ref-10", "volume": "12", "first-page": "8-9", "year": "2014", "article-title": "Increased rituximab (R) doses eliminate increased risk and improve outcome of elderly male patients with aggressive CD20+ B-cell lymphomas: the SEXIE-R-CHOP-14 trial of the DSHNHL.", "journal-title": "Clin Adv Hematol Oncol."}, {"key": "ref-11", "doi-asserted-by": "publisher", "first-page": "955-63", "DOI": "10.3324/haematol.2015.125344", "article-title": "Rituximab maintenance for patients with aggressive B-cell lymphoma in first remission: results of the randomized NHL13 trial.", "volume": "100", "author": "U Jaeger", "year": "2015", "journal-title": "Haematologica."}, {"key": "ref-12", "doi-asserted-by": "publisher", "first-page": "2920-6", "DOI": "10.1200/JCO.2012.46.9718", "article-title": "Obinutuzumab (GA101) in patients with relapsed/refractory indolent non-Hodgkin lymphoma: results from the phase II GAUGUIN study.", "volume": "31", "author": "G Salles", "year": "2013", "journal-title": "J Clin Oncol."}, {"key": "ref-13", "doi-asserted-by": "publisher", "first-page": "2912-9", "DOI": "10.1200/JCO.2012.46.9585", "article-title": "Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study.", "volume": "31", "author": "F Morschhauser", "year": "2013", "journal-title": "J Clin Oncol."}, {"key": "ref-14", "first-page": "1820", "article-title": "Safety and Efficacy Of Obinutuzumab (GA101) Plus CHOP Chemotherapy In First-Line Advanced Diffuse Large B-Cell Lymphoma: Results From The Phase 2 Gather Study (GAO4915g).", "volume": "122", "author": "A Zelenetz", "year": "2013", "journal-title": "Blood."}, {"key": "ref-15", "doi-asserted-by": "publisher", "first-page": "503-11", "DOI": "10.1038/35000501", "article-title": "Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling.", "volume": "403", "author": "A Alizadeh", "year": "2000", "journal-title": "Nature."}, {"key": "ref-16", "doi-asserted-by": "publisher", "first-page": "2313-23", "DOI": "10.1056/NEJMoa0802885", "article-title": "Stromal gene signatures in large-B-cell lymphomas.", "volume": "359", "author": "G Lenz", "year": "2008", "journal-title": "N Engl J Med."}, {"key": "ref-17", "doi-asserted-by": "publisher", "first-page": "12-23", "DOI": "10.1038/nrclinonc.2013.197", "article-title": "Diffuse large B-cell lymphoma-treatment approaches in the molecular era.", "volume": "11", "author": "M Roschewski", "year": "2014", "journal-title": "Nat Rev Clin Oncol."}, {"key": "ref-18", "author": "D Scott", "first-page": "e458-66", "year": "2015", "article-title": "Cell-of-Origin in Diffuse Large B-Cell Lymphoma: Are the Assays Ready for the Clinic?", "journal-title": "Am Soc Clin Oncol Educ Book.", "DOI": "10.14694/EdBook_AM.2015.35.e458", "doi-asserted-by": "publisher"}, {"key": "ref-19", "doi-asserted-by": "publisher", "first-page": "275-82", "DOI": "10.1182/blood-2003-05-1545", "article-title": "Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray.", "volume": "103", "author": "C Hans", "year": "2004", "journal-title": "Blood."}, {"key": "ref-20", "doi-asserted-by": "publisher", "first-page": "4836-43", "DOI": "10.1182/blood-2010-12-322362", "article-title": "Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy.", "volume": "117", "author": "G Guti\u00e9rrez-Garc\u00eda", "year": "2011", "journal-title": "Blood."}, {"key": "ref-21", "doi-asserted-by": "publisher", "first-page": "441-53", "DOI": "10.1111/bjh.12045", "article-title": "Whole genome expression profiling based on paraffin embedded tissue can be used to classify diffuse large B-cell lymphoma and predict clinical outcome.", "volume": "159", "author": "S Barrans", "year": "2012", "journal-title": "Br J Haematol."}, {"key": "ref-22", "doi-asserted-by": "publisher", "first-page": "2367-78", "DOI": "10.1158/1078-0432.CCR-14-0357", "article-title": "Reproducible, Quantitative, and Flexible Molecular Subtyping of Clinical DLBCL Samples Using the NanoString nCounter System.", "volume": "21", "author": "M Veldman-Jones", "year": "2015", "journal-title": "Clin Cancer Res."}, {"key": "ref-23", "doi-asserted-by": "publisher", "first-page": "1214-7", "DOI": "10.1182/blood-2013-11-536433", "article-title": "Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue.", "volume": "123", "author": "D Scott", "year": "2014", "journal-title": "Blood."}, {"key": "ref-24", "doi-asserted-by": "publisher", "first-page": "2848-56", "DOI": "10.1200/JCO.2014.60.2383", "article-title": "Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies.", "volume": "33", "author": "D Scott", "year": "2015", "journal-title": "J Clin Oncol."}, {"key": "ref-25", "doi-asserted-by": "publisher", "first-page": "3727-32", "DOI": "10.1158/1078-0432.CCR-10-2573", "article-title": "Accurate classification of diffuse large B-cell lymphoma into germinal center and activated B-cell subtypes using a nuclease protection assay on formalin-fixed, paraffin-embedded tissues.", "volume": "17", "author": "L Rimsza", "year": "2011", "journal-title": "Clin Cancer Res."}, {"key": "ref-26", "doi-asserted-by": "publisher", "first-page": "281-5", "DOI": "10.1111/bjh.12983", "article-title": "Molecular subtype classification of formalin-fixed, paraffin-embedded diffuse large B-cell lymphoma samples on the ICEPlex\u00ae system.", "volume": "167", "author": "A Collie", "year": "2014", "journal-title": "Br J Haematol."}, {"key": "ref-27", "doi-asserted-by": "publisher", "first-page": "273-283", "DOI": "10.1016/j.jmoldx.2015.01.007", "article-title": "Accurate Classification of Germinal Center B-Cell-Like/Activated B-Cell-Like Diffuse Large B-Cell Lymphoma Using a Simple and Rapid Reverse Transcriptase-Multiplex Ligation-Dependent Probe Amplification Assay: A CALYM Study.", "volume": "17", "author": "S Mareschal", "year": "2015", "journal-title": "J Mol Diagn."}, {"key": "ref-28", "doi-asserted-by": "publisher", "first-page": "113-20", "DOI": "10.1038/labinvest.2014.136", "article-title": "Diffuse large B-cell lymphoma: sub-classification by massive parallel quantitative RT-PCR.", "volume": "95", "author": "X Xue", "year": "2015", "journal-title": "Lab Invest."}, {"key": "ref-29", "doi-asserted-by": "publisher", "first-page": "404-10", "DOI": "10.1097/PPO.0b013e31826c5810", "article-title": "Inhibitors of B-cell receptor signaling for patients with B-cell malignancies.", "volume": "18", "author": "M Choi", "year": "2012", "journal-title": "Cancer J."}, {"key": "ref-30", "doi-asserted-by": "publisher", "first-page": "922-6", "DOI": "10.1038/nm.3884", "article-title": "Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma.", "volume": "21", "author": "W Wilson", "year": "2015", "journal-title": "Nat Med."}, {"key": "ref-31", "doi-asserted-by": "publisher", "first-page": "1019-26", "DOI": "10.1016/S1470-2045(14)70311-0", "article-title": "Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.", "volume": "15", "author": "A Younes", "year": "2014", "journal-title": "Lancet Oncol."}, {"key": "ref-32", "doi-asserted-by": "publisher", "first-page": "2803-11", "DOI": "10.1200/JCO.2014.59.5363", "article-title": "Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin Lymphoma.", "volume": "33", "author": "J Gribben", "year": "2015", "journal-title": "J Clin Oncol."}, {"key": "ref-33", "doi-asserted-by": "publisher", "first-page": "723-37", "DOI": "10.1016/j.ccr.2012.05.024", "article-title": "Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma.", "volume": "21", "author": "Y Yang", "year": "2012", "journal-title": "Cancer Cell."}, {"key": "ref-34", "doi-asserted-by": "publisher", "first-page": "730-7", "DOI": "10.1016/S1470-2045(14)70191-3", "article-title": "Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial.", "volume": "15", "author": "U Vitolo", "year": "2014", "journal-title": "Lancet Oncol."}, {"key": "ref-35", "doi-asserted-by": "publisher", "first-page": "251-7", "DOI": "10.1200/JCO.2014.55.5714", "article-title": "Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study.", "volume": "33", "author": "G Nowakowski", "year": "2015", "journal-title": "J Clin Oncol."}, {"key": "ref-36", "author": "G Nowakowski", "first-page": "e449-57", "year": "2015", "article-title": "ABC, GCB, and Double-Hit Diffuse Large B-Cell Lymphoma: Does Subtype Make a Difference in Therapy Selection?", "journal-title": "Am Soc Clin Oncol Educ Book.", "DOI": "10.14694/EdBook_AM.2015.35.e449", "doi-asserted-by": "publisher"}, {"key": "ref-37", "doi-asserted-by": "publisher", "first-page": "6069-76", "DOI": "10.1182/blood-2009-01-199679", "article-title": "Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma.", "volume": "113", "author": "K Dunleavy", "year": "2009", "journal-title": "Blood."}, {"key": "ref-38", "doi-asserted-by": "publisher", "first-page": "1893-901", "DOI": "10.1182/blood-2015-03-632430", "article-title": "Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL.", "volume": "126", "author": "F Offner", "year": "2015", "journal-title": "Blood."}, {"key": "ref-39", "volume": "14", "first-page": "15-6", "year": "2016", "article-title": "Randomized Phase 2 Open-Label Study of R-CHOP \u00b1 Bortezomib in Patients (Pts) With Untreated Non-Germinal Center B-Cell-like (Non-GCB) Subtype Diffuse Large Cell Lymphoma (DLBCL): Results From the Pyramid Trial (NCT00931918).", "journal-title": "Clin Adv Hematol Oncol."}, {"key": "ref-40", "author": "A Davies", "volume": "126", "year": "2015", "article-title": "A Prospective Randomised Trial of Targeted Therapy for Diffuse Large B-Cell Lymphoma (DLBCL) Based upon Real-Time Gene Expression Profiling: The Remodl-B Study of the UK NCRI and SAKK Lymphoma Groups (ISRCTN51837425).", "journal-title": "Blood."}, {"key": "ref-41", "doi-asserted-by": "publisher", "first-page": "107-12", "DOI": "10.1182/asheducation-2014.1.107", "article-title": "Double-hit lymphomas: current paradigms and novel treatment approaches.", "volume": "2014", "author": "K Dunleavy", "year": "2014", "journal-title": "Hematology Am Soc Hematol Educ Program."}, {"key": "ref-42", "doi-asserted-by": "publisher", "first-page": "3360-5", "DOI": "10.1200/JCO.2009.26.3947", "article-title": "Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab.", "volume": "28", "author": "S Barrans", "year": "2010", "journal-title": "J Clin Oncol."}, {"key": "ref-43", "doi-asserted-by": "publisher", "first-page": "e555-67", "DOI": "10.1016/S1470-2045(15)00005-4", "article-title": "Double-hit and double-protein-expression lymphomas: aggressive and refractory lymphomas.", "volume": "16", "author": "C Sarkozy", "year": "2015", "journal-title": "Lancet Oncol."}, {"key": "ref-44", "doi-asserted-by": "publisher", "first-page": "2375-90", "DOI": "10.1182/blood-2016-01-643569", "article-title": "The 2016 revision of the World Health Organization classification of lymphoid neoplasms.", "volume": "127", "author": "S Swerdlow", "year": "2016", "journal-title": "Blood."}, {"key": "ref-45", "doi-asserted-by": "publisher", "first-page": "3452-9", "DOI": "10.1200/JCO.2011.41.0985", "article-title": "Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.", "volume": "30", "author": "N Johnson", "year": "2012", "journal-title": "J Clin Oncol."}, {"key": "ref-46", "doi-asserted-by": "publisher", "first-page": "2253-63", "DOI": "10.1182/blood-2012-06-435842", "article-title": "MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma.", "volume": "121", "author": "H Horn", "year": "2013", "journal-title": "Blood."}, {"key": "ref-47", "doi-asserted-by": "publisher", "first-page": "4021-31", "DOI": "10.1182/blood-2012-10-460063", "article-title": "MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program.", "volume": "121", "author": "S Hu", "year": "2013", "journal-title": "Blood."}, {"key": "ref-48", "doi-asserted-by": "publisher", "first-page": "891-901", "DOI": "10.1111/bjh.12982", "article-title": "Double hit lymphoma: the MD Anderson Cancer Center clinical experience.", "volume": "166", "author": "Y Oki", "year": "2014", "journal-title": "Br J Haematol."}, {"key": "ref-49", "doi-asserted-by": "publisher", "first-page": "2354-61", "DOI": "10.1182/blood-2014-05-578963", "article-title": "Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis.", "volume": "124", "author": "A Petrich", "year": "2014", "journal-title": "Blood."}, {"key": "ref-50", "doi-asserted-by": "publisher", "first-page": "504-14", "DOI": "10.1111/bjh.13463", "article-title": "Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysis.", "volume": "170", "author": "C Howlett", "year": "2015", "journal-title": "Br J Haematol."}, {"key": "ref-51", "first-page": "395", "article-title": "Preliminary Report of a Multicenter Prospective Phase II Study of DA-EPOCH-R in MYC-Rearranged Aggressive B-Cell Lymphoma.", "volume": "124", "author": "K Dunleavy", "year": "2014", "journal-title": "Blood"}, {"key": "ref-52", "volume": "12", "first-page": "18-9", "year": "2014", "article-title": "Phase I study of ABT-199 (GDC-0199) in patients with relapsed/refractory non-Hodgkin lymphoma: responses observed in diffuse large B-cell (DLBCL) and follicular lymphoma (FL) at higher cohort doses.", "journal-title": "Clin Adv Hematol Oncol."}, {"key": "ref-53", "doi-asserted-by": "publisher", "first-page": "44-50", "DOI": "10.1200/JCO.2012.46.8793", "article-title": "Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas.", "volume": "32", "author": "J Friedberg", "year": "2014", "journal-title": "J Clin Oncol."}], "container-title": ["F1000Research"], "language": "en", "link": [{"URL": "https://f1000research.com/articles/5-1933/v1/xml", "content-type": "application/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://f1000research.com/articles/5-1933/v1/pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://f1000research.com/articles/5-1933/v1/iparadigms", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 3, 22]], "date-time": "2019-03-22T15:36:00Z", "timestamp": 1553268960000}, "score": 26.574726, "issued": {"date-parts": [[2016, 8, 8]]}, "references-count": 53, "URL": "http://dx.doi.org/10.12688/f1000research.8790.1", "relation": {"has-review": [{"id-type": "doi", "id": "10.5256/f1000research.9460.r15549", "asserted-by": "subject"}, {"id-type": "doi", "id": "10.5256/f1000research.9460.r15548", "asserted-by": "subject"}], "cites": []}, "ISSN": ["2046-1402"], "issn-type": [{"value": "2046-1402", "type": "electronic"}], "assertion": [{"value": "Indexed", "URL": "https://f1000research.com/articles/5-1933/v1#article-reports", "order": 0, "name": "referee-status", "label": "Referee status", "group": {"name": "current-referee-status", "label": "Current Referee Status"}}, {"value": "10.5256/f1000research.9460.r15548, Randy Gascoyne, Department of Pathology & Laboratory Medicine, University of British Columbia, British Columbia Cancer Agency, Vancouver, BC, USA, 08 Aug 2016, version 1, indexed", "URL": "https://f1000research.com/articles/5-1933/v1#referee-response-15548", "order": 0, "name": "referee-response-15548", "label": "Referee Report", "group": {"name": "article-reports", "label": "Article Reports"}}, {"value": "10.5256/f1000research.9460.r15549, Mark Roschewski, Lymphoma Therapeutics Section, Metabolism Branch, National Cancer Institute, NIH, 9000 Rockville Pike, Bethesda, MD, 20892, USA, 08 Aug 2016, version 1, indexed", "URL": "https://f1000research.com/articles/5-1933/v1#referee-response-15549", "order": 1, "name": "referee-response-15549", "label": "Referee Report", "group": {"name": "article-reports", "label": "Article Reports"}}, {"value": "The author(s) declared that no grants were involved in supporting this work", "order": 2, "name": "grant-information", "label": "Grant Information"}, {"value": "This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.", "order": 0, "name": "copyright-info", "label": "Copyright"}]}], "items-per-page": 20, "query": {"start-index": 0, "search-terms": null}}}